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Introduction	
In	the	Danish	Integrated	Antimicrobial	Resistance	Monitoring	and	Research	Program	DANMAP	
2012	 it	 is	 stated	 that	 the	Clostridium	difficile	 types	 containing	 the	 toxin	genes	 tcdA	and	 tcdB	
may	contribute	to	human	infections,	and	the	zoonotic	importance	of	these	types	should	be	fur‐
ther	investigated.		
	
To	evaluate	the	zoonotic	importance	of	C.	difficile	from	an	animal	reservoir,	the	National	Food	
Institute,	 Technical	 University	 of	 Denmark	 has	 at	 the	 request	 of	 the	 Danish	 Veterinary	 and	
Food	Administration,	Ministry	of	Food,	Agriculture	and	Fisheries	conducted	this	report.		
	
The	 Danish	 Veterinary	 and	 Food	 Administration	 requests	 an	 assessment	 of	 the	 overall	 im‐
portance	of	a	zoonotic	reservoir	of	C.	difficile	and	the	risk	on	human	health	associated	with	this	
reservoir.	This	report	focuses	on	answering:	
 If	the	toxins	TcdA	and	TcdB	can	cause	infections	in	humans?	
 What	is	the	incidence	of	cases	in	Denmark?	
 If	there	is	evidence,	that	the	presence	of	C.	difficile	presences	in	meat	represents	a	risk	to	
the	consumers?	
‐ Under	what	circumstances	and	conditions	is	there	a	possible	risk?	
‐ How	likely	is	the	risk?	
 If	there	is	evidence,	that	the	presence	of	C.	difficile	in	production	animals	represents	a	risk	
to	persons	working	with	infected	animals?	
‐				Under	what	circumstances	and	conditions	is	there	a	possible	risk?	
‐				How	likely	is	the	risk?	
 If	there	is	known	future	changes	in	the	production	systems	or	antibiotic	consumption	pat‐
tern	in	animals	that	may	influence	the	risk	of	humans	regarding	C.	difficile	infections?	
	
The	assessment	should	include	international	per	reviewed	literature	from	the	last	10	years	and	
available	Danish	data.	The	 report	 is	 not	 a	 systematic	 review.	This	 report	was	 conducted	be‐
tween	April	and	December	2014.		
	
Search	parameters:	C.	difficile	combined	with:	Zoonotic,	zoonoses,	 food	(including	meat	and	
ready‐to‐eat	 food),	 antibiotic	 resistance,	 surveillance,	 epidemiology,	 community	 acquired	 in‐
fections,	risk	factors,	production	animals	and	environment.			
	
Abbreviations:	
CDI	=	Clostridium	difficile	infection	
MLVA	=	Multi	Locus	Variable‐number	tandem	repeat	Analysis	
PCR	=	Polymerase	Chain	Reaction	
PFGE	=	Pulsed‐field	gel	electrophoresis	
PMC	=	Pseudomembranous	colitis		
WGS	=	Whole	genome	sequencing	
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Dansk	resumé	
Clostridium	difficile	 (C.	difficile)	 er	 en	 sporedannende	 strikt	 anaerob	 bakterie.	 Bakterien	 kan	
forekomme	naturligt	i	tarmen	hos	mennesker	og	forskellige	dyr,	som	heste,	svin,	kvæg,	fjerkræ,	
geder,	får,	gnavere,	hunde	og	katte.	C.	difficile	smitter	direkte	via	afføring,	via	person‐til‐person	
smitte	eller	 indirekte	via	sporer	efterladt	på	overflader	eller	hud.	Sporerne	er	et	dvalestadie,	
hvor	bakterien	er	inaktiv.	Sporer	kan	overleve	i	årevis	i	jord	og	støv	eller	på	arbejdstøj	og	red‐
skaber.	De	er	varmetolerante	og	modstandsdygtige	overfor	alkoholbaserede	desinfektionsmid‐
ler	 (i	 stedet	anbefales	sæbe	håndvask).	Sporerne	kan	under	de	 rette	betingelser	aktiveres	 til	
levedygtige	 bakterier,	 der	 kan	 fremkalde	 sygdom.	C.	difficile	 producerer	 forskellige	 toksiner,	
som	er	sygdomsfremkaldende	hos	mennesker.	Dels	toksinerne	TcdA	og	TcdB,	men	også	et	bi‐
nært	toksin	CDT.	Det	binære	toksin	er	forbundet	med	en	højere	dødelighed	hos	hospitalsind‐
lagte	patienter	sammenlignet	med	infektioner	forårsaget	af	C.	difficile,	der	kun	bærer	toksiner‐
ne	TcdA	og	TcdB.	Nogle	stammer	af	C.	difficile	er	højvirulente	og	producerer	en	større	mængde	
af	de	enkelte	toksiner.	C.	difficile	er	naturligt	resistent	overfor	cefalosporiner	og	kan	derudover	
bære	resistens	overfor	en	lang	række	af	antibiotika,	der	anvendes	til	behandling	af	mennesker,	
herunder	 fluoroquinoloner,	makrolider,	 tetracyklin	og	vancomycin.	Den	 infektive	dosis	 for	C.	
difficile	kendes	ikke,	men	varierer	sandsynligvis	blandt	individer,	og	er	afhængig	af	forudgåen‐
de	 behandling	 med	 antibiotika,	 bagvedliggende	 sygdom	 samt	 påvirkninger	 af	 den	 normale	
tarmflora.	
	
Infektioner	med	C.	difficile	er	en	vigtig	årsag	til	diarré,	særligt	hos	hospitalsindlagte	ældre	pati‐
enter	samt	immunkompromitterede	patienter.	Infektionen	kan	spænde	fra	en	asymptomatisk	
infektion,	til	mild	diarré,	livstruende	pseudomembranøs	colitis	(PMC),	toksisk	megacolon,	tarm	
perforering,	sepsis	og	død.	C.	difficile	infektion	(CDI)	opstår	typisk	i	forbindelse	med	antibiotika	
behandling,	som	forstyrrer	eller	fjerner	den	normale	tarmflora	og	dermed	giver	C.	difficile	op‐
timale	betingelser	for	at	formere	sig	og	producere	de	toksiner	der	forårsager	sygdom.	C.	diffici‐
le	er	resistent	overfor	en	 lang	række	antibiotika,	hvilket	kan	medføre	en	 forværret	 infektion,	
som	er	 sværere	at	behandle.	 I	 flere	 lande,	 inklusive	Danmark,	har	en	særlig	højvirulent	 resi‐
stent	variant	af	C.	difficile	med	navnet	ribotype	027	forårsaget	sygdomsudbrud	på	flere	hospi‐
taler.	 Flere	 andre	 ribotyper	 er	højvirulente	og	 associeret	med	 sygdom.	 I	Danmark	blev	der	 i	
årene	2009	–	2013	rapporteret	i	alt	4.347	C.	difficile	ribotype	027	patienter	med	virulens	toksi‐
nerne	TcdA	og	TcdB	og	det	binære	toksin.	
	
De	seneste	år	er	CDI	i	højere	grad	set	blandt	personer,	som	ikke	har	været	i	kontakt	med	sund‐
hedsvæsenet.	Disse	patienter	ofte	yngre,	og	infektionen	er	ikke	i	samme	grad	som	den	hospi‐
talserhvervede	udløst	af	forudgående	antibiotika	behandling.	Årsagen	til	stigningen	i	de	sam‐
fundserhvervede	CDI	er	ukendt.	Da	der	er	sammenfald	i	ribotyper	og	antibiotika	resistens	i	det	
humane‐	og	veterinære	reservoir,	og	da	der	er	fundet	genetisk	identiske	stammer	ved	fuld	ge‐
nom‐sekventering	(WGS)	i	begge	reservoirer	har	forskere	over	hele	verden	undersøgt,	om	fo‐
rekomsten	af	C.	difficile	i	dyr	kan	være	årsag	til	stigningen	i	de	samfundserhvervede	CDI	og	om	
C.	difficile	kan	smitte	via	 fødevarer.	En	række	 lande	 i	Europa,	heri	blandt	Holland	har	 fundet	
genetisk	identiske	ribotype	078	hos	både	smågrise	og	mennesker.	C.	difficile	ribotype	078	ses	i	
højere	 grad	 hos	 de	 samfundserhvervede	 CDI	 end	 ribotype	 027,	 som	primært	 findes	 i	 hospi‐
talsmiljøet.	 I	 Danmark	 har	man	 ligeledes	 fundet	 overlap	mellem	det	 humane‐	 og	 veterinære	
reservoir.	En	række	undersøgelser	i	Europa,	Canada	og	USA	dokumenterer	positive	fund	af	C.	
difficile	i	svinekød,	kalvekød,	kyllingekød,	grøntsager,	vand	og	jord.		
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Det	har	ikke	været	muligt	at	estimere,	hvorvidt	forekomsten	af	C.	difficile	i	fødevarer	er	årsag	
til	 human	 sygdom,	 eller	 om	 forekomsten	udgør	 en	 reel	 risiko	 for	den	 almindelige	 forbruger.	
Modtagelighed	hos	det	enkelte	individ	spiller	formentlig	en	højere	rolle	end	ved	andre	fødeva‐
rebårne	mave‐tarm	infektioner.	Der	rejses	dog	videnskabelig	bekymring	overfor	sammenfaldet	
mellem	stigningen	i	de	samfundserhvervede	CDI	og	fund	i	fødevarer	og	produktionsdyr.			
	
Ligesom	der	ikke	er	bevis	for,	at	C.	difficile	i	fødevarer	udgør	en	risiko	for	den	almindelige	for‐
bruger,	er	der	heller	 ikke	bevis	 for	at	en	arbejdsmæssig	kontakt	 til	produktionsdyr	udgør	en	
risiko	for	personer	med	almen	god	sundhedstilstand,	hvis	man	følger	de	almindelige	hygiejne‐
regler	for	området.		
	
Selvom	der	ikke	er	bevis	for,	at	C.	difficile	i	fødevarer	eller	produktionsdyr	udgør	en	risiko,	an‐
befales	det	dog,	at	følgende	områder	inden	for	fødevareproduktionen	bør	have	særlig	opmærk‐
somhed:	A)	Ændringer,	der	begunstiger	anaerobe	forhold,	som	muliggør	overlevelse	af	C.	diffi‐
cile	i	slutproduktet,	B)	brug	af	antibiotika	i	produktionsdyr,	som	kan	påvirke	forekomsten	af	C.	
difficile	i	dyrene,	C)	ændringer	i	hygiejneprocedurer	og	varmebehandlingsparametre	i	produk‐
tionskæden,	som	kan	påvirke	overlevelsen	af	C.	difficile	sporer.	
	
For	 at	 kunne	 forstå	 epidemiologien	 bag	 de	 samfundserhvervede	 CDI	 samt	 udbredelsen	 af	C.	
difficile	 i	 dyr	 og	 mennesker	 er	 der	 behov	 for	 standardiserede	 mikrobiologiske	 metoder	 og	
overvågning.	 Overvågningsprogrammer	 af	C.	difficile	 bør	 fokusere	 på	 alle	 ribotyper,	 der	 er	 i	
stand	til	at	producerer	toksiner.	
	
Sammenlignende	mikrobiologiske	undersøgelser,	der	anvender	genetisk	diskriminative	meto‐
der	af	C.	difficile	stammer	fundet	i	mennesker,	dyr,	fødevarer	og	miljø	(herunder	vand)	kombi‐
neret	med	epidemiologiske	metoder,	kan	potentielt	bidrage	til	en	bedre	forståelse	af	C.	difficile,	
og	hvorvidt	det	veterinære	reservoir	udgør	en	human	risiko.		 	
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1.	Background	
Clostridium	 difficile	 (C.	 difficile)	 is	 a	motile	 spore‐forming	 bacteria	 and	 strict	 anaerobic.	 The	
spores	of	C.	difficile	enable	the	organism	to	survive	in	adverse	conditions,	for	example	in	soil,	dust	
and	on	skin,	and	can	persist	on	environmental	surfaces	for	months	and	even	years.	Alcohol,	chlor‐
hexidine,	iodophors,	and	other	antiseptic	agents	are	ineffective	at	inactivating	C.	difficile	spores.	
The	occurrence	of	C.	difficile	suggests	a	seasonal	variation.	C.	difficile	is	the	most	commonly	diag‐
nosed	cause	of	antimicrobial‐associated	and	hospital‐acquired	diarrhea.	
1.1	Clostridium	difficile	characteristics	
C.	difficile	 is	 a	motile	 gram‐positive	 spore‐forming	 bacteria	 classified	 as	 strict	 anaerobe.	 The	
normal	location	for	C.	difficile	is	in	the	intestinal	tract	of	humans	and	various	animal	species	as	
production	animals,	horses	and	pets	(Weese	2010).	The	bacteria	are	spread	by	the	faecal–oral	
route,	 indirectly	 through	 spores	 left	 on	 surfaces	 and	 by	 person‐to‐person	 transmission	
(Hookman	&	Barkin	2009;	DePestel	&	Aronoff	2013).		
	
In	Europe,	agarose	gel‐based	polymerase	chain	reaction	(PCR1)	ribotyping	is	the	most	common	
used	 typing	method	of	C.	difficile.	 Although	PCR‐ribotyping	has	 proved	 to	 be	 useful	 to	 study	
epidemiology	on	local,	national	and	European	level,	efforts	are	made	to	replace	it	with	the	ca‐
pillary	electrophoresis	PCR‐ribotyping	in	order	to	increase	pattern	recognition,	reproducibility	
and	 interpretation.	However,	 this	method	 lacks	sufficient	discriminatory	power	to	study	out‐
breaks	 and	 therefore	 the	 typing	method	multilocus	 variable‐number	 tandem	 repeat	 analysis	
(MLVA)	 has	 been	 developed	 to	 study	 transmission	 between	 humans,	 animals	 and	 food.	 In	
North‐America,	 pulsed‐field	 gel	 electrophoresis	 (PFGE)	 is	 commonly	 used	 and	 the	 obtained	
banding	patterns	are	 referred	 to	as	NAP‐field	 types.	Various	other	 typing	methods	 for	C.	dif‐
ficile	are	used:	Restriction	 endonuclease	 analysis	 (REA),	multilocus	 sequence	 typing	 (MLST),	
tandem	repeat	sequence	 typing	(TRST)	and	whole	genome	sequencing	(WGS)	 (Knetsch	et	al.	
2013).	TRST	is	a	new	method	for	genotyping	of	C.	difficile	and	is	used	in	Denmark	for	both	hu‐
man,	veterinary	and	food	isolates.	C.	difficile	has	more	than	150	PCR	ribotypes	and	24	toxino‐
types	(Kuijper	et	al.	2006).		
1.2	C.	difficile	spores	and	survival	
C.	difficile	spores	frequently	contaminate	the	environment	around	infected	patients	and	hospi‐
talization	provides	not	only	a	reservoir,	but	also	a	vector	for	transmission	(Stanley	et	al.	2013).	
The	epidemic	strains	of	C.	difficile	(e.g.	ribotype	027)	are	believed	to	have	a	greater	sporulation	
capacity	in	vitro	than	non‐outbreak	strains	(Rupnik	2007).	The	spores	of	C.	difficile	enable	the	
organism	to	survive	in	adverse	conditions,	for	example	in	soil,	dust	and	on	skin.	The	spores,	as	
well	as	the	vegetative	form,	can	persist	on	fomites	(e.g.	cloths,	utensils)	and	environmental	sur‐
faces	for	months	(Hookman	&	Barkin	2009;	DePestel	&	Aronoff	2013)	and	even	years	(Rupnik	
et	al.	2009).		
	
Alcohol,	chlorhexidine,	iodophors,	and	other	antiseptic	agents	are	ineffective	at	inactivating	C.	
difficile	spores.	The	most	effective	to	prevent	the	transmission	of	spores	is	frequent	hand	wash	
with	soap	and	water,	rather	than	with	alcohol‐based	waterless	hand	hygiene,	especially	when	
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directly	or	indirectly	taken	care	of	patients	with	a	C.	difficile	infection	(CDI)	in	the	health	care	
system	 or	 having	 other	 contact	 to	 CDI	 patients	 (Hookman	 &	 Barkin	 2009;	 Epi‐Nyt	 Statens	
Serum	Institut	week	13;	2009World	Health	Organization	20092;).	C.	difficile	spores	have		been	
shown	 to	 survive	 the	 temperatures	 and	disinfectant	 treatment	of	 typical	hospital	 laundering	
cycles	and	to	cross‐contaminate	bed	linens	during	a	wash	cycle	(Rupnik	2007).	A	study	testing	
the	survival	of	C.	difficile	at	cooking	 temperature	71oC	showed	that	all	20	 tested	 isolates	had	
viable	spores	after	extended	heating	for	2	hours3	(120	min)	(Rodriguez‐Palacios	et	al.	2010).	A	
later	study	conducted	by	the	same	researcher	found	that	cooking	aliquots	containing	less	than	
4	log10	at	85°C	in	liquid	media	yielded	no	cultivable	spores	after	15	min	heat	treatment.	Con‐
sidering	a	concentration	of	C.	difficile	spores	in	naturally	contaminated	retail	raw	meat	prod‐
ucts	may	be	less	than	3.3	log10/g	of	product,	cooking	at	85°C	could	according	to	the	researchers	
markedly	reduce	human	exposure	to	C.	difficile	(Rodriguez‐Palacios	and	LeJeune	2011).		
1.3	Seasonality	
A	Canadian	study	performed	by	Rodriguez‐Palacios	et	al.	in	2009	suggests	a	seasonal	variation	
in	the	prevalence	of	C.	difficile	in	the	reservoir.	Meat	samples	from	retail	were	systematic	sam‐
pled	over	an	8‐month	period.	Isolation	of	C.	difficile	was	more	common	in	February	than	in	the	
other	 months,	 although	 the	 reason	 for	 this	 apparent	 seasonality	 was	 unclear	 (Rodriguez‐
Palacios	et	al.	 2009).	 In	 foods	and	 food	animals,	 according	 to	Rodriguez‐Palacios	et	al.	2013,	
three	 independent	 studies	document	higher	prevalence	 in	winter	 in	North	America.	Also	 the	
number	 of	 cases	 of	 CDI	 in	 humans	 appears	 to	 be	 higher	 during	 winter	 months,	 at	 least	 in	
northern	latitudes.	This	seasonal	increase	has	been	partly	attributed	to	a	larger	number	of	cas‐
es	associated	with	seasonal	respiratory	and	enteric	viral	 infections	that	require	antimicrobial	
administration	or	hospitalization	(Rodriguez‐Palacios	et	al.	2013),	which	both	are	known	risk	
factors	for	CDI.	
1.4	C.	difficile	infection	in	humans	
C.	difficile	causes	human	infection,	CDI.	It	is	assumed	that	disruption	of	the	normal	protective	
gastrointestinal	microbiota,	 as	 a	 result	 of	 antimicrobial	 therapy,	 is	 an	 important	 factor	 for	 a	
colonization	by	C.	difficile	 in	 the	 intestine	 and	 involves	overgrowth	by	 toxigenic	 strains	of	C.	
difficile,	 followed	by	 the	production	of	 toxins	(Hookman	and	Barkin	2009;	Weese	2010).	The	
infection	can	range	from	an	asymptomatic	colonization,	to	a	mild	self‐limiting	diarrheal	illness,	
to	 the	 life‐threatening	antibiotic‐associated	diarrhea	pseudomembranous	 colitis	 (PMC),	 toxic	
megacolon,	intestinal	perforation,	sepsis	and	death	(Hookman	and	Barkin	2009;	Keessen	et	al.	
2011;	DePestel	 and	Aronoff	2013).	Pseudomembranous	 colitis	 (PMC)	 is	an	 intestinal	disease	
which	is	characterized	by	offensive‐smelling	diarrhea,	abdominal	pain,	and	fever,	particularly	
following	 antibiotic	 treatment.	 Although	 the	 severe	 form	of	C.	difficile	 disease,	 PMC,	was	de‐
scribed	back	in	1893,	C.	difficile	was	not	linked	to	PMC,	and	little	was	known	about	the	organ‐
ism	except	that	it	was	considered	to	be	part	of	the	normal	intestinal	ecology	of	infants.	Notably	
																																																								
	
	
2	Hygienic	precautions	described	in	Statens	Serum	Institut	Epi‐Nyt	week	13	2009	and	WHO	Guidelines	on	hand	
hygiene	in	health	care,	Guide	to	appropriate	hand	hygiene	in	connection	with	Clostridium	difficile	spread,	World	
Health	Organization	2009,	pp242‐245	
3	The	Danish	Food	and	Veterinary	Administration	recommends	that	carved	meat,	minced	meat	and	mechanically	
tenderized	meat	is	thoroughly	cooked	to	at	least	a	temperature	of	75oC.	Fakta	om	Fødevarehygiejne,	Føde‐
varestyrelsen	2005	ISBN:	87‐91569‐97‐4	
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PMC	 was	 rare	 before	 the	 widespread	 use	 of	 antibiotics	 in	 the	 late	 1940s	 and	 early	 1950s	
(Rupnik	et	al.	2009).		
C.	difficile	 was	 first	 identified	 in	 the	 1970s	 as	 the	 predominate	 bacterial	 cause	 of	 antibiotic‐
associated	diarrhea	and	in	1978	reported	as	the	cause	of	antibiotic‐associated	colitis	by	criteria	
of	Koch	(Stanley	et	al.	2013).	C.	difficile	is	now	the	most	commonly	diagnosed	cause	of	antimi‐
crobial‐associated	 and	 hospital‐diarrhea,	 and	 the	most	 cases	 of	 PMC	 (Weese	 2010;	DePestel	
and	Aronoff	2013).	The	risk	of	developing	CDI	increases	if	C.	difficile	is	resistant	to	the	antimi‐
crobial	 agents	used,	which	 enables	 the	bacteria	 to	 colonize	 the	 intestine	 faster	 (Huang	 et	 al.	
2009).	
	
Individual	genetic	differences	regarding	the	sensibility	of	CDI	have	been	reported.	Individuals	
that	lack	a	host	response	to	produce	sufficient	quantities	of	antibodies	directed	against	toxin	A	
and	 those	 individuals	with	 a	 common	 single‐nucleoside	polymorphism	 in	 the	 ‐251	 region	 of	
the	interleukin‐8	gene	promoter	may	have	an	increased	risk	of	recurrences.	The	risk	of	recur‐
rences	increases	with	advanced	age,	with	patients’	≥65	years	of	age	at	highest	risk.	Disruption	
of	the	gut	microbiota	and	loss	of	colonization	resistance	have	been	investigated	as	a	risk	factor	
for	recurrence	and	provide	the	biological	basis	for	a	successful	use	of	faecal	microbiota	trans‐
plantation.	Other	risk	factors	for	recurrence	include	concurrent	use	of	antibiotics	for	non‐CDI,	
acid	 suppressing	 agents,	 exposure	 to	 the	 health	 care	 environment,	 and	 underlying	 chronic	
comorbidities	(DePestel	&	Aronoff	2013).	
	
The	infective	dose	of	C.	difficile	for	humans	is	not	known	and	probably	varies	among	individu‐
als	(Weese	2010).	Different	studies	emphasize	that	the	pathophysiology	of	CDI	is	not	yet	fully	
understood	and	in	the	recent	years	an	animal	reservoir	has	been	discussed	as	a	possible	source	
of	CDI.	
2.	The	virulence	genes	of	C.	difficile	
C.	difficile	produces	several	toxins	capable	of	introducing	human	disease.	Toxinotyping	is	a	PCR‐
based	method	and	toxin	A	and	toxin	B	were	the	first	toxins	to	be	discovered.	Some	strains	of	C.	dif‐
ficile	also	produce	the	binary	toxin	CDT.	The	role	of	the	binary	toxin	CDT	in	human	disease	is	not	
yet	fully	understood,	but	there	is	information	suggesting	that	this	toxin	may	be	clinically	relevant.	
Strains	possessing	the	binary	toxin	genes	and	genes	encoding	for	tcdA	and	tcdB,	seem	to	have	a	
higher	case‐fatality	risk,	irrespective	of	ribotype.	
2.1	Toxin	A	and	toxin	B	
C.	difficile	produces	several	toxins	capable	of	introducing	human	disease.	The	enterotoxin	toxin	
A	(TcdA)	and	a	cytotoxin	toxin	B	(TcdB),	both	belong	to a	group	of	large	clostridial	toxins.	Be‐
cause	of	 their	unusual	pattern	of	 toxin	production,	 the	TcdA	and	TcdB	strains	were	 the	 first	
variant	strains	to	be	discovered		(Weese	2010).	The	two	toxins	have	different	behaviour	affect‐
ing	the	cells;	TcdA	binds	more	effectively	on	the	apical	side	of	the	host	cell	and	TcdB	binds	to	
an	unknown	receptor	on	the	basolateral	side	of	the	host	cell.	Studies	have	shown	that	the	main	
clinical	symptoms	and	signs	of	CDI	 largely	can	be	explained	by	TcdA	and	TcdB	(Rupnik	et	al.	
2009).	 In	 the	 intestinal	 tract	 the	 toxins	 cause	 disruption	 of	 the	 actin	 cytoskeleton	 and	 tight	
junctions,	 and	 resulting	 in	 decreased	 transepithelial	 resistance,	 fluid	 accumulation	 and	 de‐
struction	 of	 the	 intestinal	 epithelium	 (Rupnik	 et	 al.	 2009).	 Most	 of	 the	 toxigenic	 C.	 difficile	
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strains	produce	both	TcdA	and	TcdB.	A	small	percentage	of	clinically	relevant	strains	produce	
TcdB	but	not	TcdA	(Weese	2010).	
2.2	Binary	toxin	CDT	and	hypervirulent	strains	of	C.	difficile	
C.	difficile	produces	also	a	binary	toxin	CDT.	The	role	of	the	binary	toxin	CDT	in	human	disease	
is	though	not	yet	fully	understood	(Rupnik	et	al.	2009;	Carter	et	al.	2012).	Previously,	the	prev‐
alence	of	binary	 toxin‐producing	strains	was	 low	(<10%);	however,	 this	has	 increased	 in	 the	
recent	 years,	 and	 binary	 toxin	 producing	 strains	 in	 some	 studies	 now	 represent	more	 than	
30%	of	isolates	from	humans	(Weese	2010).	A	Danish	study	has	shown	that	patients	with	the	
binary	toxin	had	higher	case‐fatality	rates	(28.0%)	30	days	after	diagnosis	than	patients	with‐
out	the	binary	toxin	adjusted	for	age,	sex,	and	geographic	region	(RR	1.6,	95%	[CI	1.01–2.4]).	
Similar	 case‐fatality	 rates	were	observed	 for	patients	 infected	with	 ribotype	027	or	 ribotype	
non‐027	(28.0%	and	27.8	%	respectively).	The	study	concludes,	that	the	binary	toxin	either	is	a	
marker	 for	more	virulent	C.	difficile	 strains	or	contributes	directly	 to	strain	virulence	and	ef‐
forts	to	control	CDI	should	target	all	virulent	strains	irrespective	of	PCR	ribotype	(Bacci	et	al.	
2011).	
	
Some	 strains	 of	C.	difficile	 are	 hypervirulent	 and	 several	microbial	 characteristics	 have	been	
attributed	 to	 possible	 hypervirulence,	 including	mutations	 in	 a	 regulatory	 gene	 tcdC	 causing	
hyperproduction	of	tcdA	and	tcdB,	production	of	the	binary	toxin	CDT,	antibiotic	resistance	and	
improved	 toxin	binding	 to	 target	 cells,	 increased	 sporulation,	 and	mutations	 in	 surface	 layer	
proteins	 that	 increase	 its	 adherence	 to	 intestinal	 epithelium	 (Coia	 2009;	DePestel	&	Aronoff	
2013).	
3.	Serotypes	involved	in	C.	difficile	infections	
During	the	last	decade,	human	infections	due	to	C.	difficile	have	become	more	frequent,	more	se‐
vere,	more	refractory	to	standard	therapy,	and	more	likely	to	relapse	than	in	previous	years.	This	
pattern	has	been	 seen	 throughout	 the	United	States,	Canada	and	Europe,	and	has	mainly	been	
attributed	to	the	strain	of	C.	difficile	ribotype	027.	This	ribotype	has	both	 in	North	America	and	
Europe	been	implicated	in	CDI	hospitals	outbreaks.		Also	the	emerging	binary	toxin‐positive	ribo‐
type	078	strain,	which	has	similar	mechanisms	for	hyper	production	of	toxins	as	ribotype	027,	has	
the	 last	years	received	more	scientific	attention.	Ribotype	078	 is	the	predominant	type	 found	 in	
production	animals	and	their	immediate	environment,	and	is	now	also	emerging	in	both	hospital‐	
and	community‐acquired	CDI.	In	some	European	countries	ribotype	078	are	more	frequently	re‐
ported	than	ribotype	027.		
3.1	C.	difficile	ribotype	027	
The	name	of	the	strain	BI,	NAP1/027	reflects	its	characteristics,	demonstrated	by	different	typ‐
ing	methods:	 Pulsed‐field	 gel	 electrophoresis	 (NAP1),	 restriction	 endonuclease	 analysis	 (BI)	
and	polymerase	chain	reaction	(027,	PCR	027)	(Hookman	&	Barkin	2009).	Ribotype	027	was	
first	assigned	in	1988	and	originated	from	a	28‐year‐old	woman	with	severe	pseudomembra‐
nous	colitis.	Until	March	2004,	it	was	considered	to	be	an	unimportant	and	very	rare	ribotype	
(Kuijper	et	al.	2006).	Ribotype	027	contains	genes	for	the	binary	toxin	CDT	and	has	a	genetic	
mutation	in	tcdC,	which	results	in	deregulated	expression	of	TcdA	and	TcdB,	and	can	produce	
up	to	16	times	more	TcdA	and	23	times	more	TcdB	in	vitro	than	other	strains	(Kuijper	et	al.	
2008;	Hookman	&	Barkin	2009).	
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Ribotype	 027	 has	 both	 in	 North	 America	 and	 Europe	 been	 implicated	 in	 CDI	 hospitals	 out‐
breaks.	The	outbreaks	have	been	characterized	by	an	increased	incidence	and	severity,	refrac‐
tory	to	traditional	therapy,	greater	risk	of	relapse	and	associated	with	increased	morbidity	and	
a	significant	mortality	(Kuijper	et	al.	2008;	DePestel	&	Aronoff	2013).	The	strain	also	tends	to	
infect	 hospitalised	 and	 elderly	who	 are	more	 vulnerable	 in	 terms	 of	 acquiring	 CDI,	 but	 also	
have	more	difficulties	to	recover	from	illness	 in	general	(DePestel	&	Aronoff	2013).	Ribotype	
027	has	been	detected	 in	meat;	ground	beef	and	veal,	ground	pork,	uncooked	pork	sausages	
and	other	food	sources4	(Rodriguez‐Palacios	et	al.	2009;	Songer	et	al.	2009).	Finally	the	strain	
has	s	universally	high‐level	resistant	to	fluoroquinolones	in	vitro,	which	was	infrequent	prior	
to	2001	(Hookman	&	Barkin	2009).		
	
In	Denmark	 in	2006,	Statens	Serum	 Institut	 (SSI)	detected	a	 cluster	of	 eight	patients	with	C.	
difficile	 ribotype	027	 in	a	retrospective	survey	covering	a	county	 in	South	Denmark.	The	 iso‐
lates	were	recovered	from	22	faecal	samples	that	had	been	collected	between	November	2006	
and	March	2007.	All	eight	cases	were	hospitalized.	Subsequently,	active	surveillance	was	initi‐
ated	in	the	same	region	for	the	period	June‐August	2007,	which	resulted	in	five	additional	ribo‐
type	027	cases	among	22	C.	difficile	isolates	tested.	Interestingly,	all	13	isolates	were	resistant	
to	newer	fluoroquinolones	and	cephalosporins,	but	susceptible	to	erythromycin	and	clindamy‐
cin	(Kuijper	et	al.	2008).	
3.2	C.	difficile	ribotype	078	
The	focus	in	surveillance	of	C.	difficile	strains	in	Europe	has	been	on	ribotype	027	(Kuijper	et	al.	
2008).	The	virulence	factors	are	however	not	unique	for	ribotype	027,	but	are	also	present	in	
other	ribotypes	such	as	the	emerging	binary	toxin‐positive	ribotype	078	strain	(also	known	as	
PCR	 078),	 which	 has	 similar	 mechanisms	 for	 hyper	 production	 of	 toxins	 as	 ribotype	 027	
(Kuijper	et	al.	2008).	Since	2005,	ribotype	078	has	increased	in	occurrence	both	regarding	the	
hospital‐	and	community‐acquired	CDI	(	Jones	et	al.	2013).		Noteworthy	is,	that	ribotype	078	is	
more	commonly	reported	than	ribotype	027.	In	a	pan‐European	surveillance	study	performed	
in	2008	in	34	European	countries,	ribotype	078	was	reported	as	the	third	most	prevalent	ribo‐
type	(8%)	whereas	ribotype	027	was	reported	in	5%	of	the	cases	(Freeman	et	al.	2010).	The	
same	pattern	was	seen	in	The	Netherlands	in	the	period	May	2013	–	May	2014,	where	20	hos‐
pitals	participated	in	a	sentinel	surveillance:	During	this	period	among	911	C.	difficile	isolates,	
ribotype	078	was	more	frequently	detected	(13.4%)	than	ribotype	027,	which	was	found	in	28	
isolates	(3%)	(NethMap	2014;	Eighth	Annual	Report	2014).	
	
Compared	 with	 patients	 infected	 with	 ribotype	 027,	 patients	 with	 ribotype	 078	 tend	 to	 be	
younger	with	fewer	co‐morbidities,	have	community‐acquired	CDI	and	similar	to	027	patients	
have	been	more	 likely	 to	have	 received	 fluoroquinolones	 in	 antimicrobial	 therapy.	However,	
according	 to	a	review	conducted	by	 Jones	et	al.	2013;	a	significant	proportion	of	patients	 in‐
cluded	in	a	study	of	ribotype	078	had	not	received	any	antibiotic	therapy	in	the	6	weeks	prior	
to	developing	CDI	in	the	community,	leading	to	the	hypothesis	that	there	is	a	yet	unknown	se‐
lection	mechanism	 that	 favours	 the	 emergence	of	 these	 strains	 (Jones	 et	 al.	 2013).	Although	
																																																								
	
	
4	See	section	8.2	
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similar	ribotypes	are	found	in	the	animal	and	human	reservoir	direct	transmission	of	C.	difficile	
from	animals,	food	or	the	environment	to	humans	has	not	been	proven.	Conversely,	emerging	
C.	difficile	ribotype	078	is	the	predominant	found	in	piglets,	calves,	and	their	immediate	envi‐
ronment.	Circumstantial	evidence	points	towards	a	zoonotic	potential	of	this	type	(Indra	et	al.	
2009;	Rupnik	et	al.	2009;	Jones	et	al.	2013)	
3.3	Other	C.	difficile	ribotypes	
Other	C.	difficile	ribotypes,	such	as	ribotype	0126,	056,	and	018	have	also	been	reported	to	be	
associated	with	more	complicated	disease	outcomes	carrying	the	same	virulence	genes	as	ribo‐
type	027	and	078	(Rupnik	et	al.	2009).	Ribotype	018	was	one	of	the	more	frequently	(6%)	re‐
ported	ribotypes	from	humans	in	the	pan‐European	survey	(Jones	et	al.	2013).		
3.4	Geographical	distribution	of	ribotypes	in	Europe	and	Denmark	
A	variation	in	ribotypes	within	the	European	Union	(EU)	should	be	expected.	Different	studies	
has	 shown	 that	 the	 ribotypes	 seem	 to	 vary	 between	 geographical	 areas	 and	 animal	 species	
(Rodriguez‐palacios	et	al.	2007;	Keessen	et	el.	2011;	Koene	et	al.	2012).	In	figure	1,	the	regional	
variation	within	the	EU	in	human	ribotypes	is	shown.	The	number	of	typed	isolates	per	country	
is	though	limited	and	various	in	numbers,	and	might	not	be	representative	due	to	different	re‐
porting	 systems.	 According	 to	 the	 figure,	 ribotype	 014‐020	 have	 a	 higher	 prevalence	 in	 the	
Scandinavian	countries	than	reported	in	Central	Europe	and	on	the	contrary	to	ribotype	001;	
which	seems	more	prevalent	in	Central	Europe	(Jones	et	al.	2013).		
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Figure	1	European	distribution	of	ribotypes	(Jones	et	al.	2013).	Geographical	distribution	of	C.	difficile	PCR‐
ribotypes	in	European	countries	with	more	than	five	typable	isolates,	November	2008.	Pie	charts	show	proportion	
of	most	common	PCR‐ribotypes	per	country.	The	number	in	the	centre	of	the	pie	charts	 is	the	number	of	typed	
isolates	within	the	country.	No	data	from	Greenland	and	Iceland.		
The	ribotype	distribution	in	Denmark	is	diverse.	A	Danish	cohort	investigation	of	the	incidence	
of	CDI	in	Danish	patients	attending	general	practice	from	August	2009	–	February	2011,	found	
69	 different	 ribotypes	 among	 257	 toxigenic	C.	difficile	 strains	 accessible	 for	 PCR‐ribotyping.	
Ribotype	014‐020‐077	was	the	predominant	type	found	in	28%	(72)	of	the	patients	and	were	
mainly	community‐acquired	CDI	(Table	1).		
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Table	1	Distribution	of	ribotypes	(PCR)	related	to	origin	of	infection	and	age,	Denmark	2009	‐	2011,	Søes	
et	al.	2013	(n=259)	
	
3.5	Summary	ribotypes	
Due	to	the	number	of	hospital	outbreaks	and	hospital	associated	cases	the	focus	in	the	previ‐
ous	and	current	surveillance	programs	of	C.	difficile	strains	has	been	on	ribotype	027.	The	viru‐
lence	factors	are,	however,	not	unique	for	ribotype	027,	but	are	also	present	in	other	ribotypes	
such	as	the	emerging	binary	toxin‐positive	ribotype	078	strain,	which	has	similar	mechanisms	
for	hyperproduction	of	toxins	as	ribotype	027.		Ribotype	078	is	the	predominant	type	found	in	
pigs,	 calves	and	 their	 immediate	environment,	and	has	also	 increased	 in	occurrence	 for	both	
the	 hospital‐	 and	 community‐acquired	 CDI.	 Ribotype	 078	 is	 now	more	 commonly	 reported	
than	ribotype	027	in	humans.	Other	ribotypes	have	also	been	reported	to	cause	human	disease,	
therefore	C.	 difficile	 ribotype	 027	 can	 no	 longer	 be	 considered	 the	 only	 ribotype	 associated	
with	 severe	disease,	 and	efforts	 to	 control	CDI	 should	 target	all	 virulent	 strains	of	C.	difficile	
and	not	only	ribotype	027.	The	importance	of	the	different	virulence	genes	regardless	of	ribo‐
types	should	be	taking	into	consideration	when	designing	surveillance	programs	of	C.	difficile.		
4.	Resistance	in	C.	difficile		
C.	difficile	are	not	yet	significant	resistant	to	the	antibiotics	used	in	treatment.	The	risk	of	develop‐
ing	CDI	 increases	though	 if	the	C.	difficile	strain	 is	resistant	to	the	antimicrobial	agents	used	 in	
antimicrobial	therapy.	The	occurrence	of	CDI	 is	 indirectly	 linked	to	the	use	of	antibiotics	as	CDI	
develops	in	connection	with	or	after	the	consumption	of	antibiotics.		
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C.	 difficile	 are	 naturally	 resistant	 to	 cephalosporins	 and	 display	 reduced	 susceptibility	 to	 a	
range	of	different	antimicrobials	used	for	clinical	treatment	of	human	infections	(Table	2).	The	
European	Committee	on	Antimicrobial	Susceptibility	Testing	(EUCAST)5	has	set	epidemiologi‐
cal	break‐points	 for	C.	difficile	 for	some	of	 these	antimicrobials,	and	resistance	to	 fluoroquin‐
olones	 (moxifloxacin),	 lincosamides	 (clindamycin),	 macrolides	 (erythromycin)	 and	 tetracy‐
clines	are	common	(EUCAST	2014,	includes	isolates	from	humans,	animals,	food	and	environ‐
ment).					
	
Fluoroquinolones	and	3rd‐	or	4th‐generation	cephalosporins	constitute	the	first‐line	therapy	for	
invasive	 Gram‐negative	 bacterial	 infections	 such	 as	 Salmonella	 and	E.	 coli.	 Similarly,	macro‐
lides,	 fluoroquinolones	and	on	occasion	tetracyclines	are	used	to	treat	enteric	Campylobacter	
species	infections	in	humans	when	treatment	is	considered	necessary.	A	review	conducted	by	
Dhara	Shah	et	al.	from	the	University	of	Houston	College	of	Pharmacy,	Texas,	provides	an	up‐
date	on	the	in	vitro	susceptibility	and	new	antibiotic	treatment	options	for	CDI	and	points	out	
that	a	number	of	C.	difficile	 strains	with	decreased	susceptibility	 to	metronidazole	have	been	
reported	(Shah	et	al.	2011).	Metronidazole	is	a	nitroimidazole	antibiotic	used	particularly	for	
anaerobic	bacteria	and	protozoa,	and	is	used	for	first	episodes	of	mild‐to‐moderate	CDI.	
	
Occurrence	 of	 fluoroquinolone	 resistance	 in	 C.	 difficile	 has	 been	 increasing	 for	more	 than	 a	
decade,	mainly	due	to	emergent	spread	of	the	fluoroquinolone	resistant	C.	difficile	ribotype	027	
clones	at	hospitals	(Mcdonald	et	al.	2005;	Rupnik	et	al.	2009).	The	use	of	fluoroquinolones	in	
treatment	of	patients	with	general	 infections	has	been	implicated	in	outbreaks	caused	by	the	
ribotype	027	strain	(Hookman	&	Barkin	2009).		
	
C.	difficile	strains	can	also	carry	resistance	to	vancomycin.	Vancomycin	is	used	in	the	treatment	
of	a	number	of	bacterial	infections	including	serious	infections	caused	by	Gram‐positive	bacte‐
ria	 known	or	 suspected	 to	 be	 resistant	 to	 other	 antibiotics.	 Vancomycin	 is	 recommended	 as	
treatment	for	CDI.	In	Denmark,	it	 is	believed	that	there	is	a	connection	between	an	increased	
usage	of	vancomycin	in	treatment	of	serious	CDI	and	an	increased	occurrence	of	vancomycin	
resistant	enterococcus	(VRE),	mainly	in	hospitals	on	Zealand	where	the	number	of	CDI	is	high‐
er	than	in	the	rest	of	the	country	(Epi‐Nyt	Statens	Serum	Institut	week	16/17	2014).	
	
It	has	been	speculated	if	and	how	antibiotic	resistance	is	a	driver	of	the	epidemic	of	CDI.	One	
explanation	can	be	that	the	antimicrobial	resistant	strain	of	C.	difficile	will	be	able	to	colonize	
and	multiply	in	the	gut	and	initiate	CDI	in	a	case	as	soon	as	the	normal	microbiota	is	sufficient‐
ly	disrupted,	whereas	 the	sensitive	strain	will	be	 inhibited	until	 such	 time	as	 treatment	with	
the	drug	ceased	and	the	gut	 levels	have	fallen	below	the	 inhibitory	threshold.	Furthermore	if	
the	 first	 case	 develops	 CDI,	 the	 environment	 becomes	 contaminated	 with	 spores	 of	 the	 re‐
																																																								
	
	
5	EUCAST	is	a	standing	committee	jointly	organized	by	the	European	Society	of	Clinical	Microbiology	and	Infec‐
tious	Diseases	(ESCMID),	the	European	Centre	for	Disease	Prevention	and	Control	(ECDC)	and	the	European	na‐
tional	breakpoint	committees.	EUCAST	deals	with	breakpoints	and	technical	aspects	of	phenotypic	in	vitro	antimi‐
crobial	susceptibility	testing	and	functions	as	the	breakpoint	committee	of	the	European	Medicines	Agency	(EMA)	
and	ECDC.	Most	antimicrobial	MIC	(the	minimum	inhibitory	concentration)	breakpoints	in	Europe	have	been	
harmonised	by	EUCAST.	
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sistant	C.	difficile	strain.	This,	in	turn,	increases	the	likelihood	that	subsequent	cases	will	ingest	
spores	of	 an	antibiotic	 resistant	 strain,	 rather	 than	a	 susceptible	 strain.	The	epidemiology	of	
CDI	is	therefore	complex	and	there	are	likely	to	be	a	range	of	other	drivers,	as	other	character‐
istics	of	the	epidemic	strains	themselves	(e.g.	ability	to	stimulate	toxin	production,	sporulation,	
and	ability	to	disrupt	the	normal	gut	microbiota),	host	population	factors,	hospital	hygiene	and	
infection‐control	practices,	and	the	use	of	other	drug	therapies	(Coia	2009).	It	is	important	to	
keep	 in	mind	 that	 the	 relative	 risk	of	 a	particular	 antibiotic	 and	 its	 association	with	CDI	de‐
pends	 on	 the	 local	 prevalence	 of	 strains	 and	 the	 resistance	 pattern	 to	 a	 given	 antimicrobial	
agent	(DePestel	&	Aronoff	2013).	
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Table	2	Resistance	C.	difficile,	EUCAST	2014	
	 MIC1	range	
EUCAST	
ECOFF2 Observations No.	Re‐
sistant	
%	Resistant	
EUCAST	
Cephalosporins	 ‐	 ‐ ‐ ‐ Natural	re‐
sistance	
Benzylpenicillin	 0,016‐32	 No	EOFF 2238 ‐ ‐	
Piperacillin/	
Piperacillin‐tazobactam	
0,016‐256/	
0,25‐64	
No	EOFF
No	EOFF	
930/
3089	
‐ ‐	
Amoxicillin	 0,032‐64	 No	EOFF 675 ‐ ‐	
Ertapenem	 2‐16	 No	EOFF 276 ‐ ‐	
Meropenem	 0,125‐32	 No	EOFF 584 ‐ ‐	
Ciprofloxacine	 8‐256	 No	EOFF 528 ‐ ‐	
Linezolid	 0,125‐16	 No	EOFF 215 ‐ ‐	
Fidaxomicin	 0,004‐2	 No	EOFF 1183 ‐ ‐	
Teicoplanin	 0,016‐0,5	 No	EOFF 401 ‐ ‐	
Moxifloxacine	 0,25‐128	 4.0 5225 2234	 42,76%
Clindamycin	 0,016‐>512	 16.0 5217 947	 18,20%
Rifampicin	 0,002‐128	 0.0040 3393 1986	 58,53%
Erythromycin	 0,032‐>512	 2.0 4281 2664	 62,20%
Tetracyclines	 0,008‐256	 0.25 1098 194	 17,70%
Tigecycline	 0,016‐2	 0.25 3579 16	 0,40%
Metronidazole	 0,016‐64	 2.0 7842 56	 0,71%
Vancomycin	 0,032‐32	 2.0 7955 34	 0,43%
Fusidic	acid	 0,032‐256	 2.0 1102 5	 0,45%
Daptomycin	 0,032‐4	 4.0 206 0	 Susceptible
Note:	 The	 distributions	 and	%	 resistant	 should	 never	 be	 referred	 to	 in	 any	 epidemiological	 context	 since	 data	
from	many	sources	(isolates	from	human,	animals,	food	and	environment),	time	periods	and	countries	have	been	
aggregated.	Table	from	http://mic.eucast.org,	accessed	December	2014.		
1) MIC:	The	minimum	inhibitory	concentration	(the	basis	of	phenotypic	methods).		
2) Epidemiological	cut‐offs	(ECOFFs)	have	been	used	in	preference	to	clinical	breakpoints	in	veterinary	re‐
sistance	surveillance	studies	to	describe	the	upper	MIC	limit	of	the	susceptible	peak	in	an	MIC	distribution,	
the	wild‐type	(WT)	population.		An	ECOFF	value	is	not	defined	if	too	few	isolates	are	available	or	if	the	data	
are	not	considered	sufficiently	reproducible	or	clear	enough	to	set	an	ECOFF.	Additional	distributions	are	
continually	being	added	to	the	database	and	distributions	are	reviewed	in	the	light	of	new	data.		
	
	
In	a	risk	prioritization	of	bacteria	conducted	by	the	Centers	for	Disease	Control	and	Prevention	
(CDC)	in	2013,	the	agents	were	divided	in	three	categories:	urgent,	serious,	and	cause	for	con‐
cern.	C.	difficile	was	categorised	as	an	urgent	threat	due	to	the	high	numbers	of	Americans	that	
are	affected	each	year.	In	total,	250,000	cases	of	CDI	are	hospitalised	each	year	in	the	United	
States.	In	most	of	these	cases,	the	use	of	antibiotics	was	a	major	contributing	factor	leading	to	
infection.	At	least	14,000	of	the	CDI	cases	were	fatal.	The	cases	were	mainly	hospital	associated	
infections,	but	with	the	potential	risk	that	infections	can	be	spread	from	the	hospital	environ‐
ment	to	the	community.	Although	C.	difficile,	at	this	stage,	does	not	have	significant	resistance	
to	the	antibiotics	used	to	treat	CDI,	antibiotic	resistance	was	included	in	the	threat	assessment	
because	of	C.	difficiles	unique	relationship	with	resistance	 issues,	antibiotic	use,	and	the	high	
morbidity	and	mortality	(Center	for	Disease	Control	and	Prevention	2013).		
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The	high	risk	category	is	due	to	the	high	number	of	cases,	the	high	fatality	rate,	the	fact	that	C.	
difficile	can	spread	rapidly,	and	that	it	is	of	critical	importance	to	public	health	to	identify	and	
reduce	infection.		
4.1	Resistant	C.	difficile	in	animals	in	Denmark	
In	Denmark,	an	investigation	from	2010	showed	high	levels	of	resistance	towards	clindamycin	
in	C.	difficile	from	broilers	(100	%,	n=6),	pigs	(81	%,	n=14)	and	cattle	(93	%,	n=26).	A	few	iso‐
lates	from	pigs	and	cattle	were	also	resistant	to	fluoroquinolones	(moxifloxacin,	n=1	and	n=2)	
and	one	pig	 isolate	were	resistant	 to	macrolides	(erythromycin).	None	of	 the	Danish	 isolates	
were	 resistant	 to	 metromidazole,	 which	 is	 the	 drug	 of	 choice	 for	 first	 episodes	 of	 mild‐to‐
moderate	CDI	(DANMAP	2010).	 In	2011,	the	occurrence	of	C.	difficile	 in	Danish	pig	farms	de‐
creased	from	15%	in	2010	to	2.8%	in	2011	when	the	voluntary	ban	of	cephalosporins	 in	pig	
production	was	 effectuated.	This	 could	 indicate	 that	 the	use	of	 cephalosporins	 can	 influence	
the	occurrence	of	C.	difficile.	In	the	same	period	the	occurrence	of	C.	difficile	in	cattle	at	slaugh‐
ter	was	 tested,	here	no	major	 changes	 in	 the	 antimicrobial	usage	 (including	 cephalosporins)	
had	been	made	and	notable	no	changes	in	the	occurrence	of	C.	difficile	were	observed	(15%	in	
both	years)	(DANMAP	2012).	The	data	are	though	at	present	limited	and	the	effect	of	a	reduced	
use	of	specific	antibiotics	on	the	occurrence	of	C.	difficile	in	livestock	is	unknown.		
4.2	Summary	resistance	in	C.	difficile	
C.	difficile	are	naturally	resistant	to	cephalosporins	and	according	to	EUCAST	display	reduced	
susceptibility	to	a	range	of	different	antimicrobials	used	for	clinical	treatment	of	human	infec‐
tions:	 Fluoroquinolones,	macrolides,	 tetracyclines	 and	 vancomycin.	 The	 occurrence	 of	 CDI	 is	
indirectly	linked	to	the	use	of	antibiotics,	as	CDI	develops	in	connection	with	or	after	the	con‐
sumption	of	antibiotics.	There	are	though	most	likely	a	range	of	other	drivers,	as	the	character‐
istics	of	the	C.	difficile	strains	themselves	(e.g.	the	ability	to	stimulate	toxin	production,	sporula‐
tion,	 and	 ability	 to	 disrupt	 the	 normal	 gut	microbiota)	 also	 host	 population	 factors,	 hospital	
hygiene	and	infection‐control	practices,	and	the	use	of	other	drug	therapies	are	important	fac‐
tors	 in	 order	 to	 develop	CDI.	 Although	C.	difficile,	at	 this	 stage,	 does	 not	 have	 significant	 re‐
sistance	 to	 the	 antibiotics	 used	 to	 treat	 CDI,	 antibiotic	 resistance	was	 included	 in	 the	 threat	
assessment	 conducted	 by	 CDC	 in	 2013,	 because	 of	 C.	 difficiles	 unique	 relationship	 with	 re‐
sistance	issues,	antibiotic	use,	and	the	high	morbidity.	In	Denmark,	an	investigation	in	animals	
showed	high	levels	of	resistance	towards	clindamycin	in	C.	difficile	isolates	from	broilers,	pigs	
and	cattle.	A	 few	 isolates	 from	pigs	and	cattle	were	also	resistant	 to	 fluoroquinolones.	When	
the	voluntary	ban	of	cephalosporins	in	pig	production	was	effectuated	the	occurrence	of	C.	dif‐
ficile	in	Danish	pig	farms	decreased.	This	could	indicate	that	the	use	of	cephalosporins	can	in‐
fluence	the	occurrence	of	C.	difficile.	The	effect	of	a	reduced	use	of	antibiotics	on	the	occurrence	
of	C.	difficile	in	livestock	is	unknown.		
5.	Surveillance	of	C.	difficile	in	humans	in	Europe	and	Denmark	
Surveillance	of	C.	difficile	is	at	this	stage	not	mandatory	in	the	EU,	and	focus	has	mainly	been	on	
ribotype	027	in	those	countries	that	have	established	surveillance	programs.	Therefore,	the	preva‐
lence	and	the	distribution	of	other	ribotypes	are	not	known	at	the	European	 level.	 In	Denmark,	
the	monitoring	of	ribotype	027	has	been	intensified	after	several	hospital	outbreaks.	
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5.1	Surveillance	of	C.	difficile	in	humans	in	Europe	
Consensus	 recommendations	 for	 surveillance,	 including	 case	 definitions,	 were	 published	 in	
2006	by	the	European	Centre	for	Disease	Prevention	and	Control	(ECDC)	and	in	2007	by	the	
CDC	(DePestel	and	Aronoff	2013).	Since	2005,	individual	countries	in	Europe	have	developed	
surveillance	 studies	 of	 the	 spread	 of	C.	difficile	 ribotype	 027	 and	 by	 2008,	 the	 ribotype	 had	
been	detected	in	16	European	countries6	 including	Denmark	(Kuijper	et	al.	2008).	In	Europe,	
the	incidence	of	hospital‐acquired	CDI	per	10,000	patient	days	ranges	from	0	in	Luxembourg	
and	Turkey	 to	19.1	 in	Finland.	 In	Austria	 an	 increase	of	255%	between	2003	and	2007	was	
recorded	by	the	Austrian	National	Reference	Centre	for	C.	difficile.	A	Spanish	study	reported	a	
significant	increase	in	CDI	between	1999	and	2007	from	3.9	to	12.2	cases	per	10,000	hospital‐
ized	patients	(Jones	et	al.	2013).	In	contrast,	England	and	Wales	have	seen	a	significant	reduc‐
tion	in	the	overall	number	of	CDI	cases;	by	>50%	from	2008	‐	2010.	The	reduction	in	cases	was	
associated	with	a	substantial	decrease	in	the	proportion	of	CDI	cases	caused	by	ribotype	027.	
The	reductions	in	infection	rate	and	prevalence	of	ribotype	027	were	manifested	by	a	reversal	
of	the	trend	of	increasing	reports	of	C.	difficile	related	deaths	up	until	2007,	where	the	number	
of	death	 certificates	 in	England	mentioning	C.	difficile	 decreased	between	2007	and	2010	by	
70%.	While	multiple	interventions	in	hospitals	and	healthcare	institutions	likely	contributed	to	
these	changes,	providing	timely	 information	on	which	ribotypes	were	causing	CDI	cases,	and	
especially	 clusters,	 probably	helped	 infection	 control	 teams	 to	 focus	prevention	measures	 in	
human	healthcare	more	effectively	(Jones	et	al.	2013).		
	
In	a	pan‐European	surveillance	study	performed	in	2008	in	34	European	countries,	 the	most	
frequently	 reported	C.	difficile	 toxigenic	 strains	were	 ribotype	117,	014	and	020	 (16%),	001	
(10%),	078	(8%),	018	(6%)	and	106,	027	and	002	(5%)	(Jones	et	al.	2013).	In	a	Dutch	hospital	
survey,	 the	 most	 frequent	 ribotypes	 among	 the	 911	 C.	 difficile	 isolates	 were	 ribotypes	 014	
(16%),	001	(14%),	078	(12%),	002	(6%)	and	005	(5%)	(NethMap	2014).	A	recent	survey	 in	
the	 United	 States7	 revealed	 that	 94.0%	 of	 persons	 with	 CDI	 received	 health	 care;	 of	 these,	
75.0%	had	onset	among	persons	not	currently	hospitalized,	including	recently	discharged	pa‐
tients,	 outpatients,	 and	 nursing	 home	 residents.	 The	 same	 kind	of	 data	 are	 not	 available	 for	
Europe,	but	according	to	the	author	these	data	emphasize	the	importance	of	obtaining	a	com‐
plete	patient	history	to	correctly	diagnose	community‐onset,	healthcare	associated	CDI	(Jones	
et	al.	2013).		
	
5.2	Surveillance	of	C.	difficile	in	humans	in	Denmark	
In	the	recent	years,	there	have	been	several	hospitals	outbreaks	of	C.	difficile	ribotype	027	in	
Denmark,	and	ribotype	027	is	considered	endemic	in	the	hospitals	in	the	Capital	Region	and	on	
Zealand.	As	a	result	of	these	current	hospitals	outbreaks	the	Danish	Health	and	Medicines	Au‐
thority8	has	intensified	the	monitoring	of	ribotype	027.		
																																																								
	
	
6	Austria,	Belgium,	Denmark,	Finland,	France,	Germany,	Ireland,	Luxembourg,	The	Netherlands,	Norway,	Poland,	
Spain,	Sweden,	Switzerland	and	the	United	Kingdom	(England,	Wales,	Northern	Ireland	and	Scotland)		
	
7	Conducted	by	the	Centers	for	Disease	Control	and	Prevention	(CDC)	and	identified	in	Emerging	Infections	Pro‐
gram	data	in	2010	
8	Sundhedsstyrelsen	
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5.2.1	Criteria	for	the	surveillance	of	C.	difficile	
The	national	Registry	of	Enteric	Pathogens	includes	weekly	case‐based	notifications	of	cultures	
positive	for	C.	difficile	from	all	departments	of	clinical	microbiology	of	regional	hospitals	in	the	
country.	A	second	case‐based	database,	the	C.	difficile	Microbiological	Database,	which	is	sepa‐
rate	 from	 the	 Registry	 of	 Enteric	 Pathogens,	 contains	 information	 on	 isolates	 that	 undergo	
genotypic	toxin	detection	and	PCR‐ribotyping	at	the	National	Reference	Laboratory	at	SSI.	Iso‐
lates	are	forwarded	by	the	departments	of	clinical	microbiology	if	they	are:	1)	resistant	to	fluo‐
roquinolones,	2)	if	severe	clinical	cause	is	observed,	3)	if	an	outbreak	is	suspected	or	4)	if	the	
genes	encoding	 for	 toxin	A,	 toxin	B	and	 the	binary	 toxin	are	detected	(Figure	2)	 (Bacci	et	al.	
2011).		
	
	
Figure	2	Description	of	C.	difficile	 infections	 surveillance	 in	Denmark,	with	 the	4	 groups	of	C.	difficile–
infected	patients	included	in	the	study,	week	1,	2008–week	22,	2009.	SSI	(Bacci	et	al.	2011)	
	
These	criteria	were	established	in	2007,	when	sporadic	cases	of	C.	difficile	ribotype	027	were	
found	for	the	first	time	in	Denmark.	They	were	reinforced	in	2009,	after	the	first	large	ribotype	
027	 outbreak	 involving	 different	 hospitals	 of	 the	 Copenhagen	 Capital	 Region	 (Bacci	 et	 al.	
2011).	For	laboratories	performing	diagnostics	that	includes	markers	for	ribotype	027	it	is	not	
required	to	submit	these	isolates,	unless	C.	difficile	with	toxin	TcdA,	TcdB	and	the	binary	toxin	
without	a	marker	for	027	is	detected.	These	non‐ribotype	027	coding	for	the	virulence	genes	
(tcdA,	tcdB	and	the	binary	toxin)	will	then	be	serotyped	at	SSI	(Epi‐Nyt	Statens	Serum	Institut	
week	7/8	2012).	
5.2.2	Surveillance	of	C.	difficile	ribotype	027	
In	the	Danish	surveillance	from	2009	–	2013	of	C.	difficile	ribotype	027	with	the	virulence	toxin	
TcdA,	TcdB	and	the	binary	toxin,	a	total	of	4,347	patients	were	reported	(table	3).	In	2012	and	
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2013,	the	incidence	decreased	compared	to	2011.		The	reason	for	the	high	number	of	cases	in	
2011	is	unknown.		
	
	
Table	3	C.	difficile	ribotype	027	with	toxin	A,	B	and	the	binary	toxin	in	Danish	regions,	number	of	patients	2009	‐	2013	
Year	 Copenhagen	 Zealand	 South	Denmark	 Mid	Denmark	 North	Denmark	 Denmark	total	
2009	 492	 98	 4	 3	 1	 598	
2010	 703	 152	 1	 7	 3	 866	
2011	 657	 438	 9	 12	 42	 1,158	
2012	 429	 304	 25	 13	 42	 813	
2013	 722	 136	 18	 25	 11	 912	
I	alt	 3,003	 1,128	 57	 60	 99	 4,347	
(	Source:	Statens	Serum	Institut	overvågningsdata	2009	‐	2013)	
	
In	2011,	 PCR	 ribotyping	of	677	C.	difficile	 isolates	 received	 as	part	 of	 the	 surveillance	 at	 SSI	
showed	 that	 the	 predominant	 ribotype	was	027	 (81%),	 ribotype	078	 accounted	 for	 7%	and	
ribotype	066	for	3%.	Beside	these	three	ribotypes	over	30	different	ribotypes	were	detected,		
all	 strains	were	positive	 for	TcdA,	TcdB	and	the	binary	toxin	(Epi‐Nyt	Statens	Serum	Institut	
week	7/8	2012).	It	must	be	noted,	that	these	results	not	necessarily	are	representative	for	the	
ribotypes	prevalent	in	Denmark	due	to	the	reporting	criteria	1‐4	(See	5.2.1).		
	
In	a	Danish	cohort	study	of	CDI	patients	attending	general	practice	2009	–	2011,	the	mean	an‐
nual	 incidence	was	 34/100,000	 persons.	 For	 CDI	 patients	 ≥60	 years	 of	 age,	 the	 annual	 inci‐
dence	was	46/100,000	 (Søes	 et	 al.	 2013).	 In	 comparison,	 the	 incidence	 for	 infections	due	 to	
Salmonella	and	Campylobacter	in	2011	was	21/100,000	and	73/100,000	respectively.		
	
Most	 patients	 2009	 –	 2013	were	 reported	 from	 the	 Copenhagen	 area	 (69.1%)	 and	 Zealand	
(25.9%).	This	trend	seems	to	be	the	same	for	2014	as	patients	reported	until	July	this	year	are	
from	the	Copenhagen	area,	corresponding	to	89.5%	(data	not	shown).	The	reasons	for	this	ge‐
ographical	difference	might	be	explained	by	differences	in	local	typing	methods	and	reporting	
systems,	 and	 a	 higher	 incidence	 in	 the	 capital	 area	 and	 Zealand	 (personal	 message	 Søren	
Persson,	Statens	Serum	Institut).			
	
5.2.3	Clinical	manifestation	from	the	surveillance	of	ribotype	027	
In	a	three	quarter	period	from	2008	–	20099,	SSI	registered	60	C.	difficile	cases	as	ribotype	027	
defined	by	the	resistance	and	toxin	pattern.	A	total	of	32	(54%)	were	women,	and	the	median	
age	was	81	years.	During	the	two	months	up	to	diagnosis	54	(92%)	had	been	hospitalized	at	
least	once,	and	55	(93%)	had,	according	to	their	medical	journal	received	antibiotics.	Diarrhea	
without	other	symptoms	was	reported	by	32	(53%),	while	the	other	had	severe	manifestations	
as	 clinical	 sepsis	 and	 PMC.	 In	 eight	 cases,	 CDI	might	 have	 been	 contributing	 to	 the	 cause	 of	
death.	
																																																								
	
	
9	From	week	29 of 2008 to week 10, 2009	
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5.3	Summary	surveillance		
Surveillance	of	C.	difficile	 is	at	 this	stage	not	mandatory	 in	the	EU	and	the	distribution	of	 the	
different	ribotypes	beside	027	is	not	known	at	the	European	level.	In	Denmark,	ribotype	027	is	
endemic	in	the	hospitals	in	the	Capital	Region	and	on	Zealand.	The	Danish	monitoring	of	C.	dif‐
ficile	is	based	on	four	criteria:	1)	resistant	to	fluoroquinolones,	2)	if	severe	clinical	cause	is	ob‐
served,	3)	 if	an	outbreak	is	suspected	or	4)	if	 the	genes	encoding	for	toxin	A,	toxin	B	and	the	
binary	 toxin	are	detected.	Due	 to	differences	 in	prioritizing,	 typing	methods	and	national	 re‐
porting	systems,	the	data	are	incomparable	within	both	the	EU	and	even	within	countries,	in‐
cluding	Denmark.	Some	investigations	have	been	conducted;	showing	an	increase	of	communi‐
ty‐acquired	CDI.	Ribotype	027	 is	mainly	associated	to	healthcare‐acquired	CDI,	as	a	more	di‐
verse	prevalence	of	ribotypes	are	seen	in	the	community‐acquired	CDI.	Though	an	increase	has	
been	reported	from	most	of	 the	EU	countries	England	and	Wales	have	due	to	different	 inter‐
vention	in	hospitals	and	healthcare	institutions	seen	a	notable	decrease	in	the	number	of	CDI	
and	CDI	associated	deaths.	The	importance	of	the	different	virulence	genes	regardless	of	ribo‐
types	should	be	taking	into	consideration	when	designing	surveillance	programs	for	C.	difficile.		
	
	
6.	Use	of	antibiotics	in	human	therapy	and	the	development	of	C.	difficile	in‐
fection	
C.	difficile	 is	recognized	as	 the	main	cause	of	 infectious	diarrhea	 that	develops	 in	patients	after	
hospitalization	 and	 exposure	 to	 antibiotic	 treatment.	 The	 association	 between	 antimicrobial	
therapy	and	CDI	has	been	almost	universal,	as	C.	difficile	capability	to	colonize	the	gut	only	is	pos‐
sible	if	the	normal	intestinal	microbiota	is	disrupted	by	e.g.	the	use	of	antibiotics	or	is	absent.	
	
All	antibiotics	have	been	associated	with	subsequent	CDI,	but	some	antibiotics	are	associated	
with	higher	risk	than	others,	including	penicillin,	cephalosporin	and	clindamycin	(Mcdonald	et	
al.	2005;	Hookman	and	Barkin	2009;	Rupnik	et	al.	2009).	In	general,	expanded‐spectrum	and	
broad‐spectrum	cephalosporins	and	clindamycin	are	the	most	frequently	implicated	antibiot‐
ics	in	CDI	(Freeman	et	al.	2010).	
	
Figure	3	shows	the	relationship	between	antibiotic	and	C.	difficile,	and	how	the	presence	of	an‐
tibiotic	 enables	 the	 bacteria	 to	 colonize	 the	 intestine	 after	 the	 antibiotic	 has	 disrupted	 the	
normal	gut	flora. 
	
Clindamycin	has	been	shown	 to	have	a	 large	negative	 impact	on	 the	 intestinal	microbiota	as	
seen	by	reduced	resistance	to	colonization	by	pathogens,	leading	to	a	high	risk	for	PMC	due	to	
C.	 difficile	 overgrowth.	 C.	 difficile	 may	 increase	 in	 number	 as	 a	 consequence	 of	 antibiotic‐
induced	disturbances,	in	particular	following	suppression	of	the	normal	beneficial	members	of	
the	anaerobic	microbiota	in	the	intestine	(Rupnik	et	al.	2009;	Jernberg	et	al.	2010).	During	the	
last	decade	particular,	fluoroquinolones	have	been	an	increasing	problem,	and	all	fluoroquin‐
olones	 have	 been	 implicated	 in	 CDI,	 including	 levofloxacin,	 moxifloxacin,	 gatifloxacin	 and	
ciprofloxacin	(Mcdonald	et	al.	2005;	Hookman	and	Barkin	2009;	Rupnik	et	al.	2009).	The	rise	in	
the	fluoroquinolone‐associated	risk	has	been	coincided	with	the	rising	incidence	of	C.	difficile	
ribotype	027	and	other	strains	that	carry	high‐level	fluoroquinolone	resistance	(Rupnik	et	al.	
2009).	The	excessive	use	of	these	agents	is	probably	responsible	for	the	worldwide	epidemic	of	
fluoroquinolone‐resistant	ribotype	027	infections	(Rupnik	et	al.	2009).		
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Figure	3	The	effect	of	antibiotics	on	the	normal	gut	flora	and	the	risk	of	CDI	(Rupnik	et	al.	2009).			
Patients	are	resistant	to	CDI	if	their	normal	gut	flora	is	not	disrupted	by	antibiotics	(a).	Once	antibiotic	treatment	
starts,	infection	with	a	C.	difficile	strain	that	is	resistant	to	the	antibiotic	is	more	likely	while	the	antibiotic	is	being	
administered	owing	to	the	presence	of	the	antibiotic	in	the	gut	(b).	When	the	antibiotic	treatment	stops,	the	levels	
of	 the	antibiotic	 in	 the	gut	diminish	 rapidly,	but	 the	microflora	 remains	disturbed	 for	a	variable	period	of	 time	
(indicated	by	the	break	in	the	graph),	depending	on	the	antibiotic	given	(c).	During	this	time,	patients	can	be	in‐
fected	with	either	resistant	or	susceptible	C.	difficile.	Finally,	after	the	microflora	recovers,	colonization	resistance	
to	C.	difficile	is	restored	(d)	(Rupnik	et	al.	2009).	
7.	Epidemiology	of	C.	difficile	infection	in	humans	
Antimicrobial	therapy	is	the	most	widely	reported	risk	factor	for	CDI	in	humans,	and	traditionally,	
elderly	and	hospitalized	patients	who	had	received	antibiotic	therapy	were	considered	to	be	the	
most	vulnerable	to	CDI.	Because	these	high‐risk	patients	are	primarily	located	in	healthcare	facil‐
ities,	CDI	was	regarded	as	a	primarily	nosocomial	disease	for	many	years.	This	disease	pattern	has	
changed,	as	persons	outside	hospitals	and	healthcare	facilities	increasingly	are	developing	CDI.		
7.1	Community	acquired	C.	difficile	
According	to	the	scientific	literature	there	have	been	two	main	changes	in	the	epidemiology	of	
CDI	over	the	past	10	–	15	years.	First	an	international	increase	in	the	incidence	and	severity	of	
hospital‐acquired	 CDI,	 with	 large	 outbreaks,	 high	 mortality	 rates,	 and	 poorer	 response	 to	
treatment.	This	has	been	largely	attributed	to	the	emergence	and	dissemination	of	the	virulent	
ribotype	027	but	other	factors,	such	as	the	increasing	use	of	fluoroquinolones,	may	also	be	in‐
volved.	 The	 second	 change	 has	 been	 the	 increasing	 incidence	 of	 community‐acquired	 CDI	
among	the	younger	populations	 in	 the	community,	who	were	historically	considered	to	be	at	
low	risk,	such	as	healthy	pregnant	women,	children,	patients	without	an	antibiotic	history,	and	
those	 with	 minimal	 or	 no	 recent	 health	 care	 exposure	 (Rupnik	 et	 al.	 2009;	 Weese	 2010;	
DePestel	and	Aronoff	2013).	Data	from	North	America	and	Europe	suggest	that	approximately	
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20%	 to	 27%	 of	 all	 CDI	 cases	 are	 community‐acquired,	 with	 an	 incidence	 of	 20	 to	 30	 per	
100,000	 population	 (DePestel	 &	 Aronoff	 2013).	 No	 outbreaks	 of	 CDI	 have	 been	 reported	
among	humans	 in	 the	community,	which	might	suggest	 that	host	 factors	vulnerability	 to	CDI	
are	of	more	importance	than	an	increased	exposure	to	C.	difficile	(Hensgens	et	al.	2012;	Jones	et	
al.	2013).			
	
The	reason	for	the	increased	incidence	of	community‐acquired	CDI	among	the	populations	in	
the	community	without	an	antibiotic	history,	and	those	with	minimal	or	no	recent	health	care	
exposure	is	unknown.	In	The	Netherlands,	an	overlap	between	the	location	of	pig	farms	and	the	
occurrence	of	human	C.	difficile	ribotype	078	infections	was	observed.	The	fact	that	infections	
with	 ribotype	 078	 in	 humans	 occurred	 in	 a	 younger	 population	 and	 were	 more	 frequently	
community‐acquired	than	infections	with	ribotype	027	strains,	together	with	the	fact	that	078	
is	the	predominant	ribotype	in	piglets,	suggest	a	common	source	(Hensgens	et	al.	2012).	Elder‐
ly	hospitalized	patients	receiving	antibiotics	are	though	still	the	main	group	at	risk	of	infection	
caused	by	C.	difficile	(Rupnik	et	al.	2009).	
	
7.2	Investigation	of	community	acquired	C.	difficile	infections	in	Denmark	
SSI	and	Odense	University	Hospital	have	investigated	the	incidence	of	community‐acquired	CDI	
among	patients	in	general	practice	in	Denmark.	Faecal	samples	from	the	patients	were	exam‐
ined	for	both	common	pathogenic	intestinal	bacteria	and	for	C.	difficile.	A	survey	was	conduct‐
ed	among	the	C.	difficile	positive	patients	to	identify	the	symptoms	and	risk	factors	for	commu‐
nity‐acquired	CDI.	 In	 total,	259	CDI	cases	and	455	non‐CDI	cases	were	 included	 in	the	study.	
The	study	divided	cases	in	healthcare‐acquired	and	community‐acquired	CDI10.	Overall,	69%	of	
cases	aged	≥	2	years	were	found	to	be	community‐acquired	CDI.	Cases	in	the	community,	who	
were	admitted	directly	to	hospital	because	of	severe	diarrhea,	are	missing	in	the	study,	leading	
to	a	possible	underestimation	of	community‐acquired	cases.	Toxin	A	and	B	and	genes	encoding	
for	the	binary	toxin	were	present	in	35	(25	%)	of	cases	over	2	years	of	age.	The	genes	for	the	
binary	toxin	were	found	more	often	in	cases	with	healthcare‐acquired	CDI	[12	out	of	31	cases	
(39	%)]	compared	to	community‐acquired	CDI	[27	out	of	200	cases	(14	%)]	(OR	4.0;	95	%	CI	
1.8–9.3).	 In	 total,	 69	 different	 ribotypes	were	 identified	 among	 the	 257	 toxigenic	 C.	 difficile	
strains.	Ribotype	014‐020‐077	was	 the	predominant	 type	 found	 in	72	 (28	%)	of	 the	CDI	pa‐
tients,	ribotype	027	was	present	 in	11	(4	%)	cases.	The	most	prevalent	ribotypes	among	the	
binary	toxin‐positive	C.	difficile	strains	were	ribotype	027,	066,	078,	023	and	DK005311.	Cases	
with	community‐acquired	CDI	were	found	to	be	infected	by	a	more	heterogeneous	spectrum	of	
ribotypes	than	cases	with	healthcare‐acquired	CDI.	Comparing	ribotype	014‐020‐077	to	027	in	
terms	of	origin	of	 infection,	 the	 latter	was	statistically	significantly	more	often	present	 in	pa‐
tients	with	healthcare‐acquired	CDI	compared	 to	patients	with	community‐acquired	CDI	 (OR	
56;	95	%	[CI	8.6–362])	(Søes	et	al.	2014).			
	
	
																																																								
	
	
10	Community‐acquired	CDI	cases	had	neither	been	admitted	to	hospital	in	the	6	months	prior	to	onset	of	infection	
nor	did	they	have	any	antibiotics	in	the	3	months	prior	to	onset	of	symptoms.	
11	Strains	with	a	unique	PCR‐ribotype	profile	not	matching	any	strain	in	the	reference	strain	collection	were	as‐
signed	a	DK	number.	
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It	is	interesting	that	the	cases	with	community‐acquired	CDI	have	a	more	heterogeneous	spec‐
trum	of	ribotypes	than	the	cases	with	healthcare‐acquired	CDI.	This	could	suggest	a	more	di‐
verse	 transmission	 and	 exposure	 in	 the	 cases	 of	 community‐acquired	 CDI	 than	 the	 CDI	 ac‐
quired	 in	a	healthcare	setting.	The	ribotype	data	presented	 in	 this	Danish	study	differs	 from	
what	was	 reported	 from	 both	 the	 pan‐European	 surveillance	 study	 (2008)	 and	 the	 sentinel	
surveillance	in	The	Netherlands	(2013‐2014)12,	where	ribotype	078	was	reported	more	often	
than	 ribotype	 027	 (Freeman	 et	 al.,	 2010;	 NethMap	 2014;	 Eighth	 Annual	 Report	 2014).	 This	
could	suggest	another	prevalence	of	ribotypes	in	Denmark	compared	to	The	Netherlands	and	
the	 average	 reported	 in	 the	pan‐European	 surveillance	 study.	Though	only	 a	 low	number	of	
ribotype	078	were	detected	 in	 the	Danish	 study,	 they	were	more	 frequently	 associated	with	
community‐acquired	CDI	(2%)	than	ribotype	027	(1%),	which	also	were	the	case	for	ribotype	
014‐020‐077	 of	 which	 32%	 were	 community‐acquired	 CDI	 and	 13%	 associated	 to	 a	
healthcare‐acquired	CDI.	Ribotype	027	was	the	most	often	involved	ribotype	in	the	healthcare‐
acquired	CDI	(23%)	(Søes	et	al.	2014).	All	strains	were	positive	for	TcdA,	TcdB	and	the	binary	
toxin	and	considered	to	be	hypervirulent.	
7.3	Risk	factors	for	C.	difficile	infection	in	humans	
Antimicrobial	therapy	is	the	most	widely	reported	risk	factor	for	CDI	in	humans	(Hookman	and	
Barkin	2009;	Weese	2010).	It	is	scientifically	accepted,	that	an	exposure	to	antibiotics	disrupt‐
ing	the	colonic	microbiota	in	the	intestine	is	leading	to	an	overgrowth	by	C.	difficile.	Many	pa‐
tients	are	asymptomatic	carriers	of	C.	difficile	on	hospital	admission,	and	they	may	develop	CDI	
after	they	are	treated	with	antibiotics	(Jernberg	et	al.	2010).	Exposure	to	antibiotics	not	only	
increases	the	risk	of	CDI	during	receipt	of	antibacterial	 therapy	but	also	 increases	the	risk	of	
CDI	 in	 the	3	months	after	end	of	 treatment,	with	 the	highest	risk	during	 the	 first	month.	 Im‐
portantly,	 receipt	 of	 antibiotics	 during	 and	 after	 treatment	 of	 CDI	 has	 been	 associated	with	
lower	 cure	 rates,	 prolonged	 time	 to	 diarrhea	 resolution,	 and	 a	 trend	 toward	 recurrent	 CDI	
(DePestel	 &	 Aronoff	 2013).	 A	 study	 concerning	 ripotype	 specific	 risk	 factors	 for	 CDI	 in	 The	
Netherlands	 found	 that	 prior	 use	 of	 fluoroquinolones	 (mainly	 ciprofloxacin)	was	 associated	
with	CDI	due	to	ribotype	078	(Keessen	et	al.	2013).	
	
A	Danish	case‐control	study	of	CDI	in	the	community	(both	rural	and	urban	area)	conducted	in	
2009	–	2011	confirmed	hospitalization	and	the	use	of	antibiotics	as	risk	factors	for	CDI	for	pa‐
tients	aged	≥2	years.	The	study	also	found	that	beef	consumption	was	associated	with	CDI	in	
cases	≥	2	 years	 of	 age	 (OR=5.5,	 95%	 [2.0‐15]).	 The	 research	 group	behind	 the	Danish	 study	
does	not	refer	to	similar	findings	(beef	being	a	risk	factor	for	CDI)	in	other	studies,	nor	could	it	
be	confirmed	by	the	literature	examined	by	this	report.	Ribotype	078	was	detected	in	four	out	
of	the	five	cases	reporting	beef	consumption	(Søes	et	al.	2013),	but	many	other	C.	difficile	ribo‐
types	were	also	found	to	be	present	in	the	cases	consuming	beef,	and	so	the	findings	of	ribo‐
type	O78	could	not	exclusively	indicate	beef	as	a	source	of	infection.	In	2010	in	connection	with	
the	DANMAP13	program,	both	cattle	and	pigs	were	investigated	for	the	presence	of	C.	difficile.	
																																																								
	
	
12	See	chapter	3.2	
13	DANMAP	‐	Use	of	antimicrobial	agents	and	occurrence	of	antimicrobial	resistance	in	bacteria	from	food	animals,	
food	and	humans	in	Denmark	
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Three	isolates	isolated	from	cattle	all	belonged	to	the	same	ribotype	named	DK136.	One	human	
case	with	ribotype	DK136	has	been	reported	in	Denmark	(DANMAP	2010).		
This	does	not	confirm	that	cattle	are	the	source	of	human	CDI,	but	indicate	an	overlap	between	
an	animal	and	human	reservoir.	
	
For	a	subgroup	of	cases	aged	<2	years,	including	only	cases	and	controls	without	other	general‐
ly	accepted	enteropathogens	than	C.	difficile,	contact	with	animals	was	significantly	associated	
with	CDI	(Søes	et	al.	2013).	However	infants	under	the	age	of	2	years	have	been	known	to	have	
C.	difficile	 as	part	of	 the	normal	 intestinal	ecology.	Also	many	different	animals	 species	 (dog,	
cat,	guinea	pig,	rabbit,	horse,	cattle	and	pig)	were	included	in	the	animal	category,	so	this	result	
may	not	reflect	a	risk	of	having	contact	with	production	animals,	but	having	contact	with	ani‐
mals	in	general.	It	has	been	suggested	that	exposure	to	household	contacts	with	CDI	and	chil‐
dren	less	than	2	years	of	age,	could	serve	as	a	potential	reservoir	for	transmission	(DePestel	&	
Aronoff	2013),	but	this	was	not	confirmed	by	the	Danish	study.		
	
Findings	by	Hookman	and	Barkin	(2009)	suggest	that	asymptomatic	carriers	of	epidemic	and	
non‐epidemic	C.	difficile	strains	have	the	potential	to	contribute	significantly	to	disease	trans‐
mission	 in	 long‐term	care	 facilities.	Spores	on	 the	skin	of	asymptomatic	patients	were	 trans‐
ferred	easily	 to	 investigators’	hands.	 It	 is	not	known	 if	 this	 transmission	of	C.	difficile	 spores	
play	 a	 role	 in	 community‐acquired	CDI,	 but	C.	difficile	 spores	 from	human	or	 environmental	
sources	are	presumably	a	common	sources	of	transmission	to	people	(Stanley	et	al.	2013).	
7.4	Summary	of	epidemiology	and	risk	factors	for	C.	difficile	infection	in	humans	
Over	the	past	10	–	15	years	there	has	been	an	increased	incidence	of	community‐acquired	CDI	
among	 the	younger	populations,	who	were	historically	 considered	 to	be	 at	 low	 risk,	 such	 as	
healthy	pregnant	women,	children,	patients	without	an	antibiotic	history,	and	those	with	min‐
imal	or	no	recent	health	care	exposure.	The	reason	for	this	increase	is	unknown.	Antimicrobial	
therapy	 is	 the	most	widely	 reported	 risk	 factor	 for	 CDI	 in	 humans.	A	 study	 concerning	 type	
specific	risk	factors	for	human	CDI	in	The	Netherlands	found	that	prior	use	of	fluoroquinolones	
(mainly	ciprofloxacin)	was	associated	with	CDI	caused	by	ribotype	078.	No	outbreaks	of	CDI	
have	been	reported	among	humans	 in	 the	community,	which	might	suggest	 that	host	 factors	
vulnerability	and	the	use	of	antibiotics	are	of	more	importance	than	the	exposure	to	C.	difficile.	
A	Danish	case‐control	study	for	CDI	in	the	community	confirmed	hospitalization	and	the	use	of	
antibiotics	 as	 risk	 factors	 for	 CDI	 for	 patients	 aged	≥2	years.	 The	 study	 also	 found	 that	 beef	
consumption	was	significantly	associated	with	CDI	in	cases	≥	2	years,	but	this	could	not	be	con‐
firmed	by	 the	 references	 in	 this	 report.	 The	 same	 study	 found	 that	 contact	with	 animals	 for	
children	under	2	years	of	age	was	significantly	associated	with	CDI.	However	many	different	
species	were	included	in	the	animal	category	(including	pets	and	wild	life	animals),	so	it	may	
not	reflect	a	risk	of	having	contact	to	production	animals,	but	having	contact	to	animals	in	gen‐
eral.		
It	 has	 been	 suggested	 that	 asymptomatic	 carriers	 of	 epidemic	 and	 non‐epidemic	 C.	 difficile	
strains	have	the	potential	to	contribute	significantly	to	disease	transmission	in	long‐term	care	
facilities.	 It	 is	not	known	 if	 this	 transmission	of	C.	difficile	 spores	plays	a	 role	 in	community‐
acquired	CDI,	but	C.	difficile	 spores	 from	human	or	environmental	 sources	are	presumably	a	
common	source	of	transmission.		
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8.	Investigations	of	C.	difficile	in	animals	and	food	
Several	 studies	have	examined	 if	 there	 could	be	a	possible	zoonotic	 link	between	 the	 increased	
incidence	in	humans	and	the	animal	reservoir.	It	is	therefore	reasonable	to	investigate	transmis‐
sions	routes	known	from	other	zoonotic	bacterial	agents	e.g.	Salmonella,	Campylobacter	and	Lis‐
teria.	 In	 the	recent	years	 several	 studies	 in	Europe,	Canada,	United	States,	Australia	and	Africa	
have	detected	and	confirmed	the	findings	of	C.	difficile	in	different	food,	production	animals	and	
meat	in	retail	outlets,	vegetables	(including	ready‐to‐eat	salads)	and	in	different	types	of	water.	
In	The	Netherlands	 investigators	 found	 that	 human	 isolates	 and	 porcine	 ribotype	 078	 isolates	
were	indistinguishable	evaluated	by	pulsed‐field	gel	electrophoresis	(PFGE),	multilocus	variable‐
number	tandem	repeat	analysis	(MLVA)	and	whole	genome	analysis	(WGS).	The	different	findings	
indicate	an	established	reservoir	for	C.	difficile	in	the	global	food	production	chain,	but	the	role	of	
C.	difficile	as	a	zoonotic	agent	is	not	fully	understood.	Data	are	though	limited	as	few	investiga‐
tions	have	been	reported	and	the	impact	on	CDI	are	unknown.	
8.1	C.	difficile	in	animals	
In	animals,	C.	difficile	was	mainly	known	as	an	 important	pathogen	in	horses,	although	it	has	
been	reported	to	infect	numerous	wild	and	production	animals;	poultry,	sheep,	pigs,	chickens,	
goats,	 cattle	 and	 calves	 and	C.	difficile	 are	now	a	major	 cause	of	 neonatal	 enteritis	 in	piglets	
(Songer	&	Anderson	2006;	 Indra	et	al.	2009).	Numerous	studies	have	been	conducted	as	 re‐
viewed	by	Keesen	et	al.	2011	(table	4).	 Investigators	 in	The	Netherlands	 found	that	ribotype	
078	strain	of	C.	difficile	 is	 the	second	most	common	strain	causing	human	 infections	and	 the	
same	strain	is	commonly	found	in	pigs.	A	Canadian	study	has	demonstrated	that	cattle	can	har‐
bour	toxigenic	strains	of	C.	difficile,	including	the	hypervirulent	027	strain	(Indra	et	al.	2009).	
	
Disease	in	animals	is,	as	CDI	in	humans,	associated	with	non‐protective	normal	gut	flora,	due	to	
either	 antibiotics	 or	 young	 age.	 The	 heterogeneity	 of	 the	 genotypes	 that	 have	 been	 isolated	
from	 animals	 (approximately	 30–50	 different	 ribotypes)	 is	 lower	 than	 the	 heterogeneity	 of	
human	isolates	(approximately	190	ribotypes).	This	could	be	caused	by	the	limited	number	of	
animal	typing	studies	that	have	been	performed	in	comparison	with	human	typing	studies.	The	
most	 prevalent	 ribotypes	 differ	 between	 animal	 and	 human	 populations,	 but	 a	 substantial	
number	of	ribotypes	have	been	isolated	from	both	populations	(Rupnik	et	al.	2009;	Indra	et	al.	
2009).	This	may	 suggest	 that	 the	animal	 reservoirs	and	a	 transmission	via	 food	are	possible	
sources	for	human	illness,	especially	for	community‐acquired	human	infections.	Nevertheless,	
the	exact	role	of	animals	as	source	of	CDI	is	not	yet	known	(Indra	et	al.	2009).	
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In	a	Dutch	study	published	in	2013	(Keessen	et	al.	2013),	the	investigators	compared	the	anti‐
microbial	susceptibility	profiles	of	human	and	piglet	C.	difficile	strains	ribotype	078	and	found	
that	besides	considerable	overlap	in	susceptibility	profiles,	the	human	and	porcine	strains	also	
had	great	genetic	similarity	when	evaluated	by	PFGE	and	WGS.	The	methods	showed	that	nu‐
merous	 of	 the	 human	 isolates	 and	 porcine	 ribotype	 078	 isolates	were	 indistinguishable	 (49	
and	50	respectively).	Also	the	resistance	patterns	found	in	piglets	and	in	human	isolates	highly	
overlapped	despite	a	different	antimicrobial	pressure;	the	use	of	antimicrobials	in	human	ther‐
apy	in	The	Netherlands	is	among	the	lowest	in	the	EU,	while	veterinary	use	of	antimicrobials	is	
among	the	highest.	The	investigators	concluded,	that	the	increased	incidence	of	ribotype	078	in	
association	with	community‐acquired	CDI	and	the	presence	of	ribotype	078	in	more	than	90%	
of	the	C.	difficile	positive	piglets,	strengthen	the	hypothesis	that	human	and	piglet	ribotype	078	
had	a	 common	origin	 (Keessen	et	al.	2013).	Similar	 studies,	with	 the	same	result,	have	been	
conducted	in	Austria	and	Germany	(Indra	et	al.	2009;	Schneeberg	et	al.	2013).	
	
Table	4	Prevalence	and	ribotypes	of	C.	difficile	in	animals	(Keesen	et	al.	2011)	
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8.1.1	C.	difficile	in	animals	in	Denmark	
In	Denmark	in	2010,	the	presence	of	C.	difficile	including	the	toxins	TcdA	and	TcdB	and	the	bi‐
nary	 toxin	was	 investigated	 in	production	animals.	C.	difficile	was	 isolated	 from	15	of	99	pig	
farms	(15%).	All	of	the	isolates	were	tested	for	toxin	genes	and	73%	had	all	three	toxin	genes	
whereas	27%	had	tcdA	and	tcdB.	In	samples	from	cattle	at	slaughter	29	of	192	samples	(15%)	
was	found	C.	difficile	positive	of	which	24%	contained	all	three	genes,	69%	contained	tcdA	and	
tcdB,	and	7%	contained	only	tcdA.	The	isolates	from	cattle	and	pigs	were	found	to	be	more	vir‐
ulent	as	some,	 in	addition	to	tcdA	and	tcdB,	also	contained	the	genes	encoding	for	the	binary	
toxin.	The	 isolates	with	 the	 three	 toxin	genes	present	were	ribotyped,	and	ribotype	078	was	
detected	in	6	out	of	the	18	isolates	from	pigs	(4)	and	cattle	(2).	The	rest	belonged	to	ribotypes	
rarely	or	not	previously	 found	 in	humans	 in	Denmark	(DANMAP	2010).	Findings	of	ribotype	
078	in	Danish	pigs	are	not	surprising	since	this	type	is	known	to	be	common	among	pigs	and	
corresponds	with	findings	in	other	countries.	
	
High	 levels	 of	 resistance	were	 detected.	Most	 isolates	were	 resistant	 to	 clindamycin	 (87%).	
However,	all	isolates	were	susceptible	to	vancomycin	and	metronidazole.	Both	vancomycin	and	
metronidazole	 are	used	 in	 antibiotic	 treatment	of	CDI.	One	 isolate	 from	pigs	and	one	 isolate	
from	cattle	were	 resistant	 to	erythromycin.	Moreover,	one	 isolate	 from	pigs	was	resistant	 to	
moxifloxacin.	This	isolate	contained	all	three	toxin	genes	and	belonged	to	a	ribotype	DK135	not	
previously	found	in	humans	(DANMAP	2010).	A	follow‐up	study	in	2012,	investigated	the	oc‐
currence	of	C.	difficile	in	pig	farms,	cattle	at	slaughter	and	in	meat	samples	collected	from	retail	
and	outlets	in	Denmark	to	determine	if	humans	via	meat	are	exposed	to	virulent	C.	difficile	iso‐
lates	 originating	 from	production	 animals.	 The	 study	 showed	 a	 decrease	 of	C.	difficile	 in	 pig	
farms	compared	to	the	previous	years,	which	may	be	explained	by	a	reduction	close	to	zero	of	
cephalosporin	consumption	in	the	same	period	(DANMAP	2012).	The	occurrence	of	C.	difficile	
was	generally	low	in	meat	and	none	of	the	most	virulent	types	containing	the	binary	toxin	were	
observed	in	the	meat	although	present	in	cattle	and	pigs.	In	broiler	flocks	at	slaughter;	6	of	197	
(3%)	were	found	positive	and	all	six	isolates	contained	TcdA	and	TcdB	(DANMAP	2012).		
8.1.1	C.	difficile	in	pets	
Since	we	live	in	close	contact	with	our	pets,	it	is	plausible	to	hypothesize	that	they	could	both	
be	a	reservoir	and	a	transmission	route	for	C.	difficile.	Several	studies	have	investigated	sam‐
ples	from	dogs	and	cats,	but	mainly	non‐toxigenic	strains	of	C.	difficile	have	been	isolated.	This	
was	also	the	conclusion	of	a	Canadian	study	in	2009,	where	investigation	of	dogs	in	the	house‐
hold	as	the	source	of	CDI	showed	no	evidence	that	dogs	were	a	significant	source	of	household	
C.	difficile	 contamination	 (Weese	et	al.	2010).	There	have	 though	been	positive	 findings	of	C.	
difficile	in	pets.	A	large	study	in	South	Wales	in	the	mid‐90s	investigated	100	dogs	and	100	cats	
and	found	C.	difficile	strains	in	10.0%	of	the	dogs	and	in	2.0%	of	the	cats.	Three	of	these	strains	
(2	dogs	and	1	cat)	were	found	positive	for	TcdA	(Saif	and	Brazier	1996;	Freeman	et	al.	2010).	
The	findings	suggest	that	the	pet	reservoir	should	not	be	neglected,	but	the	impact	is	unknown	
as	are	the	routes	of	transmission.		
	
8.2	C.	difficile	in	food	of	animal	origin	
The	 first	 specific	 investigation	of	C.	difficile	 contamination	of	retail	meat	 intended	 for	human	
consumption	was	a	study	from	Canada	in	2007	by	Rodriguez‐Palacios	et	al.	The	study	involved	
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a	convenience	sample	of	ground	beef	(n	=	53)	and	veal	(n	=	7).	C.	difficile	was	isolated	from	12	
of	60	(20%)	samples	(21%	ground	beef	and	14%	ground	veal).		
The	most	common	strain,	accounting	for	67%	of	the	isolates,	was	a	toxigenic	strain	that	pos‐
sessed	genes	encoding	for	the	toxins	TcdA,	TcdB	and	the	binary	toxin	CDT	(Rodriguez‐palacios	
et	al.	2007).	Since	the	first	findings,	several	studies	in	Africa,	Australia,	Canada,	Europe	and	the	
United	States	have	confirmed	the	ability	of	C.	difficile	to	be	present	in	different	food,	production	
animals,	vegetables	and	meat	at	retail	(table	5).		
	
Table	5	Prevalence	of	isolation	and	ribotype	distribution	of	C.	difficile	from	food	animals	and	retail	meat	
(Weese	2010)	
		
In	Europe,	studies	from:	Slovenia	(Pirs	et	al.	2008),	Sweden	(Von	Abercron	et	al.	2009),	Austria	
(Jöbstl	et	al.	2010),	France	(Bouttier	et	al.	2010),	The	Netherlands	(Koene	et	al.	2012;	De	Boer	
et	al.	2011)	and	Germany	(Schneeberg	et	al.	2013)	have	investigated	the	occurrence	of	C.	dif‐
ficile	in	the	food	production	chain.	In	all	the	studies	mentioned,	different	levels	of	toxigenic	C.	
difficile	strains	have	been	detected	in	both	animals	and	food	of	animal	origin.	This	raises	scien‐
tific	concern	regarding	the	possible	risk	of	human	exposure	to	C.	difficile	from	food.	This	con‐
cern	is	supported	by	other	studies	(Rodriguez‐palacios	et	al.	2007;	Indra	et	al.	2009;	Keessen	et	
al.	2011),	but	no	clear	association	has	been	found	between	the	occurrence	in	the	animal	reser‐
voir	and	 in	humans.	The	source	of	C.	difficile	 in	meat	 is	not	clear,	but	carcasses	may	become	
contaminated	with	 faecal	material	or	 from	the	environment	during	 the	slaughtering	process.	
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Contamination	 at	 retail	 level	 may	 also	 occur	 from	 the	 processing	 environment	 or	 through	
transmission	by	food	handlers.	The	excellent	survival	of	C.	difficile	spores	in	the	environment	
increases	the	possibilities	for	contamination	of	animals	and	foods	(De	Boer	et	al.	2011).		
 
In	Canada	in	2006,	a	total	of	28	C.	difficile	 isolates	were	cultured	from	13	meat	packages	(22	
from	ground	beef,	6	from	veal).	PCR‐ribotyping	showed	8	distinct	genotypes,	7	of	which	were	
toxigenic	and	present	in	10	(77%)	meat	packages.	Genotypes	resembling	human	ribotype	027	
were	found	in	30.8%	(n=4)	of	positive	samples,	and	ribotypes	077	and	014,	formerly	reported	
in	cattle	and	retail	meats,	were	identified	in	23.1%	(n=3)	and	15.4%	(n=2)	of	the	samples,	re‐
spectively.	Multiple	 genotype	 contamination	was	 also	 documented.	 PFGE	 confirmed	 that	 se‐
lected	meat	and	human	ribotypes	were	identical.	Fluoroquinolone	and	clindamycin	resistance	
was	common	among	the	tested	isolates	(41.6%–58.3%).	Although	ingestion	of	spores	does	not	
necessarily	 imply	 infection,	 this	 study	 supports	 the	 potential	 for	 foodborne	 transmission	
(Rodriguez‐Palacios	et	al.	2009).	Even	though	the	data	represents	few	samples,	the	presence	of	
C.	difficile	ribotype	077	and	014,	and	the	high	level	of	resistance	in	the	meat	isolates	are	of	con‐
cern	as	these	specific	ribotypes	are	among	the	most	common	in	community‐acquired	CDI	in	the	
EU	including	Denmark.		
	
Different	C.	difficile	ribotypes	 involved	 in	human	disease	have	been	detected	 in	both	produc‐
tion	animals	and	in	food	products.	A	study	from	the	United	States,	using	convenience	sampling	
from	stores	reported	isolation	of	C.	difficile	from	different	types	of	meat	and	ready‐to‐eat	sau‐
sages	 in	37	of	88	(42%)	samples.	Ribotype	078	was	 the	most	common	strain,	accounting	 for	
73%	of	the	isolates,	with	the	remaining	isolates	belonging	to	ribotype	027	(Songer	et	al.	2009).	
Recent	studies	have	identified	C.	difficile	in	retail	meat,	including	pork,	beef	and	turkey,	with	a	
predominance	of	ribotype	027	and	ribotype	078	strains	(Weese	et	al.	2010).	A	study	by	Indra	
et	al.	from	2009	indicates	together	with	other	reports	that	the	rate	of	C.	difficile	contaminated	
meat	 in	 Europe	 is	 lower	 than	 reported	 from	 the	United	 States,	 but	 this	might	 have	 changed	
during	the	past	five	years	(Indra	et	al.	2009).	
	
In	Sweden,	82	meat	samples	were	evaluated	to	estimate	the	occurrence	of	C.	difficile	 in	retail	
ground	meat.	C.	difficile	was	 isolated	from	two	ground	beef	samples	from	two	different	retail	
shops	collected	on	two	different	sampling	occasions	(May	and	September	2008).	The	meat	was	
of	Swedish	origin	and	both	C.	difficile	isolates	were	found	positive	for	TcdA	and	TcdB.	No	C.	dif‐
ficile	was	isolated	from	pork,	sheep,	hamburger,	poultry,	or	other	type	of	meat.	(Von	Abercron	
et	al.	2009).	Even	though	the	Swedish	findings	were	few,	they	did	raise	some	concern	in	Swe‐
den	as	both	isolates	were	considered	toxigenic	for	humans.	
	
In	Denmark,	besides	pigs	and	cattle,	poultry	meat	has	also	been	investigated	in	the	DANMAP	
program.	 Here	 a	 higher	 prevalence	was	 observed	 in	 broiler	meat	 (7%)	 compared	with	 pigs	
(2.8%	 in	2011).	Whether	 the	 findings	were	due	 to	differences	 in	 the	 slaughter	processes	 for	
broilers	compared	to	pigs	or	differences	in	occurrence	in	the	animals	is	not	known.	The	occur‐
rence	of	C.	difficile	in	cattle	at	slaughter	was	15%	(DANMAP	2012).	
8.3	C.	difficile	in	other	food	products,	water	and	environment	
Although	contamination	of	retail	meat	has	received	the	most	attention,	contamination	of	other	
food	products	may	be	equally	important,	particularly	for	those	that	are	eaten	after	little	clean‐
ing	 or	 cooking.	 There	 are	 various	 possible	 sources	 of	 contamination	with	 C.	 difficile	 spores,	
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which	both	can	be	of	human	or	animal	origin,	such	as	soil,	 fertilizer	(manure),	contaminated	
water,	processing	environments,	or	from	human	hands.	Few	investigations	of	other	food	prod‐
ucts	have	though	been	reported	(Weese	2010).	
 
	
Two	 studies	of	C.	difficile	 in	 vegetables	 (in	 South	Wales	 and	Canada)	 reported	 isolation	of	C.	
difficile	 from	different	 types	of	vegetables	(root	vegetables14,	mushrooms,	cucumber	and	gin‐
ger)	 (Weese	2010;	Metcalf	 et	 al.	2010).	A	Scottish	 study	described	 isolation	of	C.	difficile	 be‐
tween	May	–	June	2008	from	three	of	40	(7.5%)	ready‐to‐eat	salads	from	seven	different	su‐
permarket	brands.	The	salads	were	not	of	UK	origin.	Isolates	were	identified	as	toxigenic;	posi‐
tive	for	both	TcdA	and	TcdB,	and	resistant	to	clindamycin	and	cefotaxime,	one	isolate	was	also	
resistant	to	moxifloxacin	and	erythromycin		(Bakri	et	al.	2009;	Weese	2010).	Though	the	num‐
bers	of	studies	are	limited,	the	findings	of	C.	difficile	strains	in	vegetables	and	ready‐to‐eat	sal‐
ads	indicate	a	possible	transmission	routes	for	CDI.	Findings	of	resistant	C.	difficile	are	not	only	
restricted	 to	 food	of	animal	origin.	Resistant	 strains	have	also	been	 isolated	 from	vegetables	
and	ready‐to‐eat	salads	(Bakri	et	al.	2009;	Weese	2010).		
	
In	a	large	study	of	the	distribution	of	C.	difficile	in	the	environment	of	South	Wales	(UK)	from	
the	mid‐90s,	the	highest	occurrence	of	C.	difficile	was	obtained	from	river	and	seawater	sam‐
ples	 (87.5%	 and	 44.0%	 respectively).	 C.	 difficile	 was	 also	 isolated	 from	 swimming	 pools	
(50.0%)	 and	main	 tap	water	 (5.5%).	 In	 private	 residences,	 the	 organism	was	 present	 in	 12	
(2.2%)	of	550	samples,	whereas	2.4%	of	300	 raw‐vegetable	 samples	were	positive	 (Saif	and	
Brazier	1996;	Freeman	et	al.	2010).		
	
The	presence	of	C.	difficile	in	vegetables,	salads	and	different	types	of	water	could	be	the	result	
of	contamination	from	the	environment	or	from	infected	food	handlers,	as	both	scenarios	are	
known	from	foodborne	outbreak	investigations	of	other	pathogens.	The	findings	suggest	that	
food	of	non‐animal	origin	could	present	a	risk	of	CDI	in	humans.	However,	data	are	limited	and	
the	impact	on	human	disease	unknown.					
8.4	Limitation	in	data	
Only	 a	 limited	 number	 of	 studies	 have	 been	 published,	 and	 these	 have	 typically	 involved	 a	
small	 number	 of	 geographical	 regions,	 with	 different	 sampling	 methods	 and	 culture	 tech‐
niques.	These	methodological	variations	preclude	the	comparison	of	prevalence	data	from	dif‐
ferent	studies.	Furthermore,	it	is	apparent	that	there	is	significant	variation	in	C.	difficile	colo‐
nization	among	different	age	groups	 in	calves,	piglets	and	chickens,	with	C.	difficile	 rates	de‐
creasing	substantially	over	 time	 (Weese	2010).	The	use	of	different	methods	 in	 the	different	
European	countries	requires	further	improvement	of	C.	difficile	detection	in	foods	(De	Boer	et	
al.	2011),	 and	 there	are	currently	no	standard	methods	 for	 isolation	of	C.	difficile	 from	retail	
meat	(Weese	2010). 
8.5	Summary	C.	difficile	in	animals	and	food		
Direct	 transmission	 of	C.	difficile	 from	 animals,	 food	 or	 the	 environment	 to	 humans	 has	 not	
been	proven,	although	similar	ribotypes	are	found.	 In	The	Netherlands,	ribotype	078	isolates	
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from	humans	and	pigs	have	been	found	to	be	indistinguishable	by	PFGE,	MLVA	and	WGS.	As	no	
outbreaks	of	CDI	have	been	reported	among	humans	 in	 the	 community,	host	 factors	 that	 in‐
crease	vulnerability	to	CDI	might	be	of	more	importance	than	increased	exposure	to	C.	difficile.	
Conversely,	 the	emerging	C.	difficile	 ribotype	078	 is	 found	 in	high	numbers	 in	piglets,	 calves,	
and	 their	 immediate	 environment.	As	 the	 ribotype	 also	 is	 present	 in	humans,	 circumstantial	
evidence	points	towards	a	zoonotic	potential	of	this	type.	There	is	scientific	concern	regarding	
the	possible	risk	of	human	exposure	to	C.	difficile	 from	food,	but	there	 is	no	clear	association	
between	the	occurrence	in	the	animal	reservoir	and	in	humans.	It	is	important	to	keep	in	mind	
that	 only	 a	 limited	number	of	 studies	have	been	published	with	different	 sampling	methods	
and	culture	techniques.	The	presence	of	C.	difficile	in	vegetables,	salads	and	different	types	of	
water	could	be	the	result	of	contamination	from	the	environment	(including	manure)	or	from	
infected	food	handlers,	as	both	scenarios	are	known	from	foodborne	outbreak	investigation	of	
other	pathogens.	The	findings	suggest	that	food	of	non‐animal	origin	could	be	a	cause	and	pre‐
sent	a	risk	of	CDI	in	humans.	Data	are	though	limited	and	the	impact	on	human	disease	is	un‐
known.					
	
Even	though	the	role	of	C.	difficile	as	a	zoonotic	agent	 is	not	 fully	understood	and	the	role	of	
food	products	and	a	possible	foodborne	transmission	in	association	to	CDI	is	either	unclear	or	
unknown,	 the	detection	of	 genes	encoding	 for	 the	virulent	 toxins	TcdA,	TcdB	and	 the	binary	
toxin	in	food	intended	for	human	consumption	should	be	considered	as	problematic	and	a	risk	
for	C.	difficile	transmission	to	humans.	Also	a	substantial	number	of	ribotypes	have	been	isolat‐
ed	 from	 both	 humans	 and	 animals	 suggesting	 that	 animal	 reservoirs	 and	 transmission	 via	
foods	of	animal	origin	or	via	the	environment	are	possible	sources	for	human	illness,	especially	
for	community‐acquired	human	infections.	Nevertheless,	the	exact	role	of	animals	as	source	of	
human	CDI	is	not	yet	known.	
	
9.	The	risk	of	C.	difficile	in	different	meat	types	estimated	by	BIOHAZ	and	
CONTAM	
Following	a	request	 from	the	European	Commission	to	EFSA15,	the	Panel	on	Biological	Hazards	
(BIOHAZ)	and	the	Panel	on	Contaminants	 in	the	Food	Chain	(CONTAM)	were	asked	to	deliver	a	
Scientific	Opinion	on	 the	public	health	hazards	 to	be	covered	by	 inspection	of	different	 types	of	
meat.	C.	difficile	was	a	part	the	public	health	hazards	discussed	by	the	two	panels.	
9.1.	The	risk	from	C.	difficile	in	poultry	meat	estimated	by	BIOHAZ	and	CONTAM	
Based	on	the	risk	ranking	in	the	Scientific	Opinion	on	the	public	health	hazards	to	be	covered	
by	inspection	of	poultry	meat,	the	hazards	from	poultry	meat	regarding	C.	difficile	were	classi‐
fied	 as	 follows:	Data	 for	 ranking	C.	difficile	were	 insufficient,	 but	 based	 on	 the	 limited	 infor‐
mation	available,	the	risk	at	the	present	time	was	considered	to	be	low.	Data	on	reported	cases	
of	C.	difficile	were	not	available	at	the	EU	level.	No	data	on	the	occurrence	of	C.	difficile	in	poul‐
try	flocks	or	carcasses	were	available	from	the	EU	monitoring	data,	and	the	proportion	of	cases	
caused	by	poultry	meat	was	unknown.	Given	the	scarcity	of	data	in	both	humans	and	animals,	
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it	was	not	currently	possible	to	determine	the	role,	if	any	that	poultry	meat	plays	in	the	epide‐
miology	of	human	 infections	with	C.	difficile,	 but	based	on	 the	 limited	available	evidence	 the	
BIOHAZ	 Panel	 concluded	 that	 the	 risk	 at	 the	 present	 time	 is	 low	 (EFSA	 Journal	
2012;10(6):2741)	.			
9.2	C.	difficile	risk	from	bovine	meat	estimated	by	the	Panel	of	BIOHAZ	
Following	 a	 request	 from	 the	 European	 Commission,	 the	 EFSA	 Panel	 on	 Biological	 Hazards	
(BIOHAZ)	was	asked	to	deliver	a	Scientific	Opinion	on	the	public	health	hazards	to	be	covered	
by	inspection	of	bovine	meat.	The	Panel	notes	that	C.	difficile	are	present	in	meat,	but	as	there	
was	no	evidence	of	meat‐borne	transmission	and	that	CDI	according	to	the	Panel	are	a	noso‐
comial	 infection	 the	Panel	considers	no	risk	 from	C.	difficile	 from	bovine	meat	 (EFSA	 Journal	
2013;11(6):3266)	
9.3	C.	difficile	risk	from	pig	meat	estimated	by	the	Panel	of	BIOHAZ	
Following a request from the European Commission, the Panel on Biological Hazards (BIOHAZ) 
and the Panel on Contaminants in the Food Chain (CONTAM) were asked to deliver a Scientific 
Opinion on the public health hazards (biological and chemical respectively) to be covered by inspec-
tion of pigs (swine). C. difficile has been isolated from fresh pork but there is currently no evidence 
of human disease attributable to this source (unknown because of lack of data). The Panel classifies 
C. difficile in pigs to be at preliminary low risk (EFSA Journal 2011;9(10):2351 2011).		
9.4	C.	difficile	risk	from	sheep	and	goats	meat	estimated	by	the	Panel	of	BIOHAZ	
Following	 a	 request	 from	 the	 European	 Commission,	 the	 EFSA	 Panel	 on	 Biological	 Hazards	
(BIOHAZ)	was	asked	to	deliver	a	Scientific	Opinion	on	the	public	health	hazards	to	be	covered	
by	inspection	of	meat	from	several	animal	species	including	sheep	and	goats’	meat.	The	EFSA	
Panel	concludes;	that	there	are	reports	of	C.	difficile	being	isolated	from	small	ruminants.	How‐
ever,	 there	was	 to	 date	 no	 indication	 of	meat‐borne	 transmission	 to	 humans	 (EFSA	 Journal	
2013;11(6):3265)	
9.5	Summary	of	the	risk	of	C.	difficile	in	meat	estimated	by	BIOHAZ	and	CONTAM	
In	general,	 the	scientific	 reports	conducted	by	 the	Panels	of	BIOHAZ	and	CONTAM	regarding	
the	hazards	from	food	regarding	CDI	confirm	the	insufficient	knowledge	in	the	area,	both	re‐
garding	lack	of	data	and	knowledge	of	the	transmission	routes.	Regarding	the	risk	from	poul‐
try,	the	BIOHAZ	Panel	conclude	that	the	risk	at	the	present	is	low	based	on	the	limited	available	
evidence.	C.	difficile	are	present	in	pig	meat,	but	there	is	no	evidence	of	meat‐borne	transmis‐
sion	and	C.	difficile	in	pigs	is	classified	to	be	at	preliminary	low	risk.	According	to	the	BIOHAZ	
Panel	on	bovine	meat,	CDI	is	exclusively	a	nosocomial	infection	and	therefore	the	Panel	consid‐
ers	no	hazard	from	bovine	meat.	C.	difficile	has	been	isolated	from	small	ruminants,	but	there	is	
to	date	no	indication	of	meat‐borne	transmission	to	humans	from	goats	or	sheep.	
	
10.	C.	difficile	transmission	from	production	animals	to	humans	
In	contrast	to	healthcare‐acquired	CDI,	where	patient‐to‐patient	transmission	 is	more	 likely,	di‐
rect	or	indirect	animal	contact	(including	contact	with	food	of	animal	origin)	is	a	more	plausible	
means	of	 transmission	 for	 community‐acquired	CDI.	Other	possible	 community	 sources	 for	CDI	
include	soil,	water,	pets	and	vegetables.	Nevertheless,	 the	exact	role	of	animals	as	source	of	hu‐
	
	
	
34	
	
	
	
man	CDI	is	not	yet	known.	No	direct	transmission	from	animals	to	humans	has	to	our	knowledge	
been	described.		
	
10.1	C.	difficile	in	production	animals	
The	levels	and	trends	of	C.	difficile	 in	production	animals	are	not	known	or	are	uncertain.	In‐
vestigation	in	The	Netherlands	showed	isolation	rates	in	samples	from	food	animals	(3.4%	in	
cattle,	 5.8%	 in	poultry	 and	6.6%	 in	pigs),	which	were	 found	 in	 agreement	with	other	 recent	
European	reports,	with	isolation	frequencies	up	to	3%	in	meat	samples	and	5%	in	samples	tak‐
en	from	animals	prior	to	slaughter	(Indra	et	al.	2009).	Studies	performed	in	the	United	States	
and	Canada	reported	the	presence	of	C.	difficile	in	food	animals	and	meat	with	rates	up	to	42%,	
(Rodriguez‐Palacios	et	al.	2009;	Weese	et	al.	2009;	Songer	et	al.	2009).	This	may	reflect	differ‐
ences	 in	 geographical	 and/or	 temporal	 variation	 in	C.	difficile	 prevalence,	 although	other	 as‐
pects,	such	as	age	of	the	sample	animals,	could	play	a	role.	The	numbers	of	animals	carrying	C.	
difficile	 may	 also	 differ	 between	 individual	 animals,	 and	 from	 farm	 to	 farm	 even	within	 the	
same	region	(Koene	et	al.	2012).	The	gastrointestinal	tract	in	animals	is	however	most	likely	an	
important	source	of	C.	difficile	contamination	and	various	comparative	genotyping	studies	sug‐
gest	that	the	predominant	strains	causing	CDI	in	humans	and	various	animal	species	are	iden‐
tical.		
10.2	C.	difficile	transmission	to	humans	
Besides	considering	a	 foodborne	transmission	of	C.	difficile	other	routes	of	 transmissions	be‐
tween	 production	 animals	 and	 humans	 should	 be	 considered;	 animals’	 hides,	 the	 slaughter‐
house	environment,	 the	processing	 facility	environment,	processing	equipment,	 the	hands	of	
personnel	handling	meat,	and	any	other	environment	where	meat	is	handled	or	processed	pri‐
or	to	sale.	C.	difficile	spores	are	highly	resistant	to	most	disinfectants,	and	can	survive	common	
cleaning	and	disinfection	practices,	and	persist	or	accumulate	in	the	environment.	Retail	meat	
might	be	contaminated	during	processing.	Personnel	in	the	food	production	and	food	handlers	
might	 be	 exposed	 to	 C.	 difficile	 spores.	 The	 risk	 and	 the	 health	 impact	 from	 these	 possible	
transmission	routes	are	unknown.	The	high	sporulation	rate	of	C.	difficile	ribotype	027	is	spec‐
ulated	to	cause	a	persisting	presence	of	the	strain	in	the	hospital	environment.	It	is	hypothet‐
ical	 plausible,	 that	 this	 high	 sporulation	 rate	 also	 could	be	 an	 important	 component	 of	 envi‐
ronmental	persistence	 in	 slaughterhouses	and	meat‐processing	environments	 (Weese	2010).	
This	is	so	far	only	a	theory	raised	in	literature.	
	
The	different	studies	suggest	an	epidemiological	connection	between	the	reservoir	of	produc‐
tion	animals	and	the	human	reservoir,	though	the	connection	is	yet	unknown	or	not	fully	un‐
derstood.	
10.2	C.	difficile	‐	a	possible	risk	for	people	who	work	with	production	animals	
It	is	known	that	C.	difficile	spores	can	be	transferred	between	persons	by	their	hands,	and	that	
persons	can	be	infected	with	C.	difficile	spores	from	hospital	environment	(Stanley	et	al.	2013).		
Presumably	these	routes	of	transmission	could	also	happen	from	the	skin	of	C.	difficile	positive	
animals,	(which	often	are	contaminated	with	manure)	and	outdoor	environment	infected	with	
C.	difficile	spores.	Few	investigations	of	the	impact	on	CDI	of	C.	difficile	from	the	environment	
have	though	been	published.	In	The	Netherlands	two	herds	of	piglets	suffering	from	diarrhea	
proved	to	be	excreting	C.	difficile	toxinotype	V,	ribotype	078.	Investigation	at	the	farm	showed	
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that	 none	 of	 the	 farm	 workers	 and	 none	 of	 the	 family	 members	 of	 the	 farm	 owners,	 even	
though	probably	exposed,	had	developed	CDI	(Freeman	et	al.	2010).	This	might	highlight	the	
importance	of	individually	sensibility	and	host	factors.		
	
Keeping	in	mind	that	the	exposure	to	C.	difficile,	the	infective	dose	of	C.	difficile	and	the	individ‐
ually	sensibility	are	unknown,	it	is	very	difficult	to	give	a	qualified	estimation	of	a	possible	risk	
of	CDI	 for	persons	working	with	production	animals	or	persons	having	contact	 to	known	 in‐
fected	animals.	As	mentioned	earlier	in	this	report,	it	is	assumed	that	a	disruption	of	the	nor‐
mal	protective	gastrointestinal	microbiota,	as	a	result	of	antimicrobial	therapy	is	an	important	
factor	 for	 colonization	 by	 C.	 difficile	 and	 that	 the	 risk	 of	 CDI	 depends	 on	 individual	 circum‐
stances	 (e.g.	 underlying	 illness,	 antibiotic	 therapy,	 microbiota	 resistance),	 and	 on	 the	 re‐
sistance	pattern	of	the	C.	difficile	strain.	It	could	be	assumed	that	a	person	with	high	sensibility	
having	contact	to	animals	carrying	toxigenic	strains	of	C.	difficile	could	be	at	risk	of	CDI,	if	per‐
sonal	hygiene	precautions	were	not	taken	(e.g.	hand	wash,	change	of	working	clothes).	The	risk	
would	assumable	be	higher	if	the	animal	is	excreting	C.	difficile.	
10.3	Summary	C.	difficile	transmission	from	production	animals	to	humans	
The	 literature	 suggests	 an	 epidemiological	 association	 between	 production	 animals	 and	 hu‐
mans	 though	 the	association	 is	not	 fully	understood.	No	direct	 transmission	 from	animals	 to	
humans	has	to	our	knowledge	been	described.	Comparative	genotyping	studies	suggest	though	
that	the	predominant	strains	causing	CDI	in	humans	and	various	animal	species	are	identical.	
Other	routes	than	foodborne	transmission	should	be	considered;	e.g.	animals’	hides,	the	envi‐
ronment	 of	 slaughterhouses	 and	processing	 facilities,	 and	 the	 hands	 of	 personnel.	C.	difficile	
spores	are	highly	resistant	to	most	disinfectants,	and	can	survive	common	cleaning	and	disin‐
fection	practices,	and	persist	 for	 long	 in	the	environment.	 It	should	be	kept	 in	mind,	 that	 the	
exposure	of	C.	difficile	is	unknown,	the	infective	dose	of	C.	difficile	is	unknown	and	the	individu‐
ally	 sensibility	 is	 unknown,	 therefore	 it	 is	 not	 possible	 to	 estimate	 a	 risk	 of	 CDI	 for	 persons	
working	with	production	animals	or	persons	having	contact	to	known	infected	production	an‐
imals.	It	could	though	be	assumed;	that	a	person	with	high	sensibility	having	contact	to	animals	
carrying	toxigenic	strains	of	C.	difficile	could	be	at	risk	of	CDI,	if	personal	hygiene	precautions	
were	not	taken.		
11.	Future	changes	in	the	food	production	system	which	may	influence	the	
risk	to	humans.	
The	knowledge	of	C.	difficile	as	a	cause	of	human	disease	and	the	presence	of	C.	difficile	in	animals	
and	food	products	has	increased	during	the	last	decades,	but	many	factors	in	the	risk	of	CDI	and	
the	background	for	the	increase	in	the	community‐acquired	CDI	remains	unknown.	It	can	though	
be	assumed	that	a	change	in	the	veterinary	antibiotic	consumption	would	lead	to	a	change	in	the	
resistance	pattern	and	in	the	occurrence	of	C.	difficile.	Also	changes	in	the	production	system	that	
favour	anaerobic	conditions	could	influence	the	growth	of	C.	difficile.	Changes	in	the	hygiene‐	and	
heat	treatment	procedures	could	allow	spores	to	survive	in	the	production	chain.	
11.1	Changes	in	the	food	production	system	
Changes	in	the	food	production	system	or	changes	in	the	occurrence	of	C.	difficile	in	production	
animals	and	food	are	not	the	only	factors	which	may	influence	the	human	incidence	of	CDI.	The	
proportion	of	elder	citizens	will	rise	globally,	and	therefore	more	CDIs	are	expected	to	occur	in	
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the	future,	as	elderly	in	general	are	at	higher	risk	(Rodriguez‐Palacios	et	al.	2013).	The	change	
in	the	population	demographics	will	put	a	higher	pressure	on	the	healthcare	system	in	general,	
but	also	 in	requirements	 to	 the	 food	production	networks	delivering	 food	 to	vulnerable	per‐
sons	in	the	healthcare	system.	
	
	
	
Though	 little	 is	known	of	C.	difficile	 in	 the	production	 system,	 the	 capability	of	 survival	of	C.	
difficile	spores,	the	abilities	of	the	spores	to	persist	on	fomites	and	the	resistance	profile	of	C.	
difficile	allow	us	to	believe	that	four	areas	are	considered	as	important:		
A)	Changes	that	favour	anaerobic	conditions	
B)	Antimicrobial	treatment		
C)	Changes	in	hygiene	procedures	
D)	Changes	in	heat	treatment.		
11.1.1	Anaerobic	conditions	
The	strains	of	C.	difficile	are	strictly	anaerobic,	which	means	that	the	bacteria	are	killed	at	nor‐
mal	concentration	of	oxygen,	which	prevents	the	bacteria	from	growing	and	establishing	in	an	
aerobe	environment.	Changes	in	food	production	which	favour	anaerobic	growth	could	though	
influence	the	occurrence	of	C.	difficile	and	other	anaerobic	bacteria	in	the	food.	This	should	be	
taken	 into	consideration,	especially	 in	regards	to	ready‐to‐eat	products	(without	heath	treat‐
ment)	produced	for	consumers	that	are	vulnerable	to	CDI	(e.g.	elderly,	hospitalised,	history	of	
antibiotic	treatment).		
11.1.2	Veterinary	antibiotic	consumption	pattern	
In	Denmark	in	2011,	an	investigation	showed	that	a	reduction	close	to	zero	in	the	consumption	
of	 cephalosporins	 in	 the	 pig	 production	may	 have	 decreased	 the	 occurrence	 of	C.	difficile	 in	
pigs16	in	the	same	period	(DANMAP	2012).	The	use	of	fluoroquinolones	in	the	early	2000s	led	
to	an	increase	in	the	fluoroquinolone	resistance	in	C.	difficile	ribotype	027	(Hookman	&	Barkin	
2009).	C.	difficile	has	reduced	susceptibility	to	a	range	of	different	antimicrobials	used	for	clini‐
cal	treatment	of	human	infections.	There	seem	to	be	an	association	between	the	antibiotic	con‐
sumption	and	the	resistance	pattern	of	C.	difficile.	It	is	also	likely	that	the	occurrence	of	C.	dif‐
ficile	in	livestock	increases	as	a	result	of	antimicrobial	usage	especially	the	use	of	cephalospor‐
ins	which	C.	difficile	is	intrinsic	resistant	to,	but	this	is	not	well	studied.	
11.1.3	Use	of	recycled	hot	water	and	lack	in	heating	and	hygiene	procedures	
C.	difficile	spores	are	besides	being	highly	resistant	to	desiccation	and	chemicals	also	resistant	
to	extreme	temperatures	(Rupnik	et	al.	2009).	If	changes	are	made	in	these	parameters	it	might	
influence	the	occurrence	of	C.	difficile	spores	in	the	food	production	and	in	the	community.		
	
Some	concern	has	been	raised	in	a	Scientific	Opinion	done	by	EFSA	regarding	the	use	of	recy‐
cled	 hot	water	 at	 slaughterhouses	 and	 the	 risk	 of	 contamination	 from	 heat‐resistant	 spores	
among	others	C.	difficile.	For	carcass	decontamination	purposes,	only	use	of	potable	water	 is	
currently	allowed	in	the	EU.	However,	recycling	of	water	(i.e.	reusing	after	reheating)	used	for	
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carcass	 decontamination	 has	 been	 practiced	 in	 some	 countries	 (e.g.	 Canada,	 Denmark).	 The	
Scientific	 Opinion	 points	 at	 different	 potential	microbiological	 risks	 for	 carcasses	 associated	
with	recycled	hot	water	decontamination.		
The	microbiological	 risks	 in	 the	 recycled	water	 of	main	 potential	 concern	 derive	 from	heat‐
resistant	bacterial	spores	such	as:	B.	cereus,	C.	botulinum,	C.	perfringens	and	C.	difficile,	however	
there	 is	a	 lack	of	data	on	 the	extent	of	 carcass	contamination	with	spores,	 their	germination	
and	 inactivation	during	 the	 recycling	process,	 and	 the	potential	 for	accumulation,	during	 the	
operations.	According	to	the	Scientific	Panel,	the	spores	of	C.	difficile	generally	can	survive	the	
79.5°C	temperature	of	the	recycled	hot	water	operation	described	for	the	Danish	system.	Alt‐
hough	a	certain	proportion	of	the	spores	may	die	if	exposed	for	several	hours	to	these	temper‐
atures	(e.g.,	spores	entering	the	water	at	start	of	the	day),	additional	spores	are	likely	to	be	in‐
troduced	 in	 the	 water	 throughout	 the	 day	 as	 new	 carcasses	 are	 processed,	 and	 dis‐
solved/suspended	proteins	and	fat	may	provide	protection	and	enhance	their	survival	(EFSA	
Journal	2010).	If	the	prevalence	of	C.	difficile	spores	on	carcasses	is	increasing	it	could	be	theo‐
retically	assumed,	that	also	the	prevalence	of	the	spores	in	the	recycling	water	would	increase	
with	the	risk	of	contaminating	the	production.		
	
C	difficile	spores	have,	as	previously	mentioned,	been	shown	to	survive	the	temperatures	and	
disinfectant	treatment	of	typical	hospital	laundering	and	to	cross‐contaminate	other	linen	dur‐
ing	 the	 laundry	procedure	(Rupnik	2007).	Theoretically,	 spores	(if	present)	can	be	spread	 in	
the	same	way	in	a	laundry	system	of	a	food	production	(e.g.	washing	of	clothing	and	towels),	if	
the	water	is	not	adequately	heated.	A	study	found	that	cooking	aliquots	containing	less	than	4	
log10	 at	 85°C	 in	 liquid	 media	 yielded	 no	 cultivable	 spores	 after	 15	 min	 heat	 treatment	
(Rodriguez‐Palacios	and	LeJeune	2011).		
	
Alcohol,	 chlorhexidine,	 iodophors,	 and	other	 antiseptic	 agents	 are	 shown	 to	be	 ineffective	 at	
inactivating	the	spores	of	C.	difficile.	The	most	effective	to	prevent	the	transmission	of	spores	is	
frequent	hand	wash	with	soap	and	water,	rather	than	with	alcohol‐based	waterless	hand	hy‐
giene	(	Epi‐Nyt	Statens	Serum	Institut	week	13	2009;	Hookman	&	Barkin	2009;	World	Health	
Organization	200917).	We	assume	that	during	the	 last	years,	 the	usage	of	alcohol‐based	hand	
hygiene	in	the	general	population	has	 increased,	maybe	also	 in	food	production	facilities	and	
institutions	(e.g.	schools	and	kindergartens).	 If	hand	washing	with	soap	and	water	in	general	
has	been	replaced	and	not	combined	with	alcohol‐based	hand	hygiene	this	could	imply	a	sur‐
vival	of	C.	difficile	spores,	which	could	lead	to	a	transmission	of	spores	in	the	general	popula‐
tion,	 in	the	food	production	and	institutions.	The	Danish	Veterinary	and	Food	Administration	
and	 the	Danish	Health	 and	Medicines	Authority	 already	 recommend	 hand	wash	 in	 their	 hy‐
giene	information.	
11.2	Summary	future	changes	in	the	food	production	chain	
When	the	epidemiology	and	hazards	concerning	C.	difficile	and	CDI	is	not	fully	understood,	it	is	
very	difficult	to	make	predictions	of	the	impact	of	 future	changes	in	the	food	production	sys‐
																																																								
	
	
17	Hygienic	precautions	described	in	SSI,	Epi‐Nyt,	week	13,	2009	and	WHO	Guidelines	on	hand	hygiene	in	health	
care,	Guide	to	appropriate	hand	hygiene	in	connection	with	Clostridium	difficile	spread,	World	Health	Organization	
2009,	pp242‐245	
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tem.	It	is	though	believed	that	the	following	areas	should	have	special	attention:	Changes	that	
favour	anaerobic	conditions	in	the	food	production	which	enables	survival	of	C.	difficile	in	the	
final	product,	antimicrobial	treatment	in	production	animals	which	might	influence	the	preva‐
lence	 of	C.	difficile	 in	 the	 animals,	 changes	 in	 hygiene	 procedures	 and	 heat	 treatment	 in	 the	
production	chain	which	might	influence	the	survival	of	C.	difficile	spores.		
12.	Preventive	measures	to	reduce	C.	difficile	
CDI	is	mainly	recognised	as	a	problem	in	hospitals,	and	outbreaks	due	to	C.	difficile	have	only	been	
seen	in	hospitals.	The	recommendations	for	the	prevention	and	control	of	CDI	are	therefore	fo‐
cused	on	health	care	settings.	Some	papers	have	though	given	recommendation	regarding	
measures	to	reduce	spread	from	animals	and	food.	
12.1	Prevention	in	hospital	settings	and	nursing	homes	
On	behalf	of	the	European	C.	difficile	Infection	Control	Group	and	ECDC	the	following	evidence‐
based	guidance	and	recommendations	for	the	prevention	and	control	of	CDI	and	C.	difficile	out‐
breaks	has	been	published	(Vonberg	et	al.	2008)	in	order	to	limit	the	spread	of	C.	difficile	in	
healthcare	settings:	
	
 Early	diagnosis	of	CDI		
 Surveillance	of	CDI	cases		
 Education	of	the	hospital	and	cleaning	personnel	as	well	as	patients	and	visitors	
 Appropriate	use	of	isolation	precautions		
 Hand	hygiene	(hand	wash	with	soap	and	water)	
 Protective	clothing		
 Environmental	cleaning	and	cleaning	of	the	medical	equipment		
 Responsible	antibiotic	therapy,	and		
 Specific	measures	during	outbreaks.	
	
Because	alcohol	is	ineffective	at	killing	C.	difficile	spores,	health	care	workers	must	frequently	
wash	their	hands	with	soap	and	water,	rather	than	with	alcohol‐based	waterless	hand	sanitiz‐
ers,	especially	when	taking	care	of	CDI	patients.	 In	hospitals	and	nursing	homes	in	Denmark,	
patients	with	ribotype	027	are	already	isolated	in	a	private	room	with	private	toilet,	to	prevent	
the	infection	from	spreading.	Staff	must	wear	gloves	and	cover	suit	coat	during	care	and	treat‐
ment	of	the	patient.	To	reduce	the	transmission	of	C.	difficile	spores,	environmental	disinfection	
with	10%	sodium	hypochlorite	and	hand	washing	with	soap	and	water	can	be	effective	at	re‐
moving	 the	 spores	 from	 hands	 and	 surfaces	 (Hookman	 &	 Barkin	 2009;	 World	 Health	
Organization	200918;	Epi	Nyt	week	13,	200919).		
	 	
																																																								
	
	
18	WHO	Guidelines	on	hand	hygiene	in	health	care,	Guide	to	appropriate	hand	hygiene	in	connection	
with	Clostridium	difficile	spread,	World	Health	Organization	2009,	pp242‐245	
19	Hygienic	precautions	described	in	SSI,	Epi‐Nyt,	week	13,	2009	
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12.2	Prevention	in	animals	and	food	
The	advice	to	healthcare	institutions	regarding	hand	washing	with	soap	and	water	in	order	to	
reduce	 the	 spread	 and	 transmission	 of	C.	difficile	 spores	 could	 also	 be	 beneficial	 in	 the	 food	
production,	in	the	general	population,	kinder	gardens,	schools	and	other	places	where	spores	
can	 be	 transmitted.	Where	 food	 is	 prepared	 to	 vulnerable	 persons	 in	 the	 community	 or	 in	
healthcare	settings;	 food	should	be	ensured	 to	be	heated	 to	more	 than	85°C	as	a	 simple	and	
important	 intervention	 to	 reduce the	 risk	 of	 inadvertent	 ingestion	 of	 C.	 difficile	 spores	
(Rodriguez‐Palacios	and	LeJeune	2011).		
	
In	 supplement	 to	 the	 recommendations	 in	healthcare	 settings,	Alex	Rodriguez‐Palacios	 et	 al.	
(2013)	has	raised	the	need	for	new	recommendations	concerning	animals	and	food	to	reduce	
the	exposure	to	C.	difficile:	
	
 Contact	precautions	regarding	human	and	animals	with	CDI,	healthy	pets	and	wild	ani‐
mals	
 Cleaning	and	disinfection	–	Addressing	food,	home,	kitchen	and	laundry	environments	
 Thorough	cooking	–	Current	food	safety	guidelines	are	ineffective	against	C.	difficile	
 As	C.	difficile	could	still	survive	cooking	temperatures	and	multiply	in	heated	foods,	it	is	
also	 recommended	 that	 foods	 should	 be	 properly	 chilled	 and	 stored	 as	 indicated	 for	
other	clostridia	foodborne	pathogens.	
	
Some	extra	hygienic	consideration	should	be	taken	for	persons	in	antibiotic	therapy	in	order	to	
minimize	the	direct	contact	to	production	animals,	or	improved	hygienic	standards	in	order	to	
prevent	the	transmissions	from	C.	difficile	spores	in	the	environment.				
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Conclusion	
C.	difficile	produces	the	enterotoxin	A	(TcdA)	and	a	cytotoxin	B	(TcdB)	both	capable	of	 intro‐
ducing	human	disease.	Some	C.	difficile	strains	also	produce	the	binary	toxin	CDT.	The	binary	
toxin	is	either	a	marker	for	more	virulent	C.	difficile	strains	or	contributes	directly	to	strain	vir‐
ulence.	The	infective	dose	of	C.	difficile	for	humans	is	unknown	and	probably	varies	among	in‐
dividuals,	depending	on	health	status	and	individual	susceptibility.	Antimicrobial	therapy	is	the	
most	widely	reported	risk	 factor	 for	CDI	 in	humans.	Antibiotic	consumption	may	disrupt	 the	
colonic	microbiota,	which	enables	the	toxigenic	C.	difficile	strains	to	colonize	the	gut.	C.	difficile	
can	either	be	present	in	the	intestine	or	be	introduced.	If	the	strains	are	resistant	to	the	antibi‐
otics	used	in	therapy	the	overgrowth	by	C.	difficile	may	be	more	rapid	and	more	severe.		
	
There	is	no	conclusive	evidence	that	the	presence	of	C.	difficile	in	meat	represents	a	risk	to	the	
consumer.	There	is	though	scientific	concern	regarding	the	possible	risk	of	human	exposure	to	
C.	 difficile	 from	 food	 (including	 vegetables).	 An	 increase	 of	 community‐acquired	 CDI	 in	 a	
younger	population	without	 antibiotic	 history	 and	 recent	health	 care	 exposure	has	been	ob‐
served,	and	CDI	with	ribotype	078	is	found	to	be	more	often	community‐acquired	than	infec‐
tions	with	ribotype	027.	Considerable	overlap	between	strains	found	in	the	animal	and	human	
reservoir	have	been	documented,	especially	ribotype	078	found	in	animals	have	been	shown	to	
have	genetic	 similarity	 to	 strains	 found	 in	humans.	 In	a	Dutch	 study	of	piglets,	 ribotype	078	
isolates	were	 indistinguishable	on	MLVA	and	WGS	 from	those	 found	 in	humans,	but	no	clear	
association	has	been	found	and	the	transmission	routes	are	unknown.		
	
It	is,	at	this	stage,	not	possible	to	estimate	the	consumers’	risk	of	CDI	from	food.	Even	exposed	
to	C.	difficile,	the	risk	of	CDI	depends	on	individual	circumstances	and	sensibility	(e.g.	underly‐
ing	 illness,	 antibiotic	 therapy,	microbiota	 resistance),	 and	on	 the	 resistance	pattern	of	 the	C.	
difficile	strain.		
	
To	our	knowledge	no	direct	transmission	from	animals	to	humans	has	been	described.	The	risk	
for	working	with	production	animals	should	be	considered	as	low	if	respecting	general	hygien‐
ic	precautions	described	for	the	area.	The	spores	of	C.	difficile	enable	the	organism	to	survive	in	
adverse	conditions	and	they	are	resistant	to	most	disinfectants.	Hazards	could	be	indirect	con‐
tact	with	animals	via	the	environment	(manure),	the	animals’	hides,	the	environment	of	slaugh‐
terhouses	 and	 processing	 facilities.	 It	 could	 be	 assumed,	 that	 a	 person	with	 high	 sensibility	
having	 contact	with	animals	 carrying	 toxigenic	 strains	of	C.	difficile	 could	be	at	 risk	of	CDI	 if	
personal	hygiene	precautions	were	not	taken.		
	
When	the	epidemiology	and	hazards	concerning	C.	difficile	and	CDI	is	not	fully	understood,	it	is	
very	difficult	 to	draw	conclusions	about	 the	 impact	of	 future	changes	 in	 the	 food	production	
system.	It	is	though	believed	that	4	areas	should	have	special	attention:	A)	Changes	that	favour	
anaerobic	 conditions	 in	 the	 food	production	which	 enables	 survival	 of	C.	difficile	 in	 the	 final	
product.	B)	Antimicrobial	 treatment	 in	production	animals	which	might	 influence	 the	preva‐
lence	and	resistance	pattern	of	C.	difficile	in	the	animals.	C)	Changes	in	hygiene	procedures	and	
D)	 Heat	 treatment	 in	 the	 production	 chain	 which	 may	 influence	 the	 survival	 of	 C.	 difficile	
spores.		
The	use	of	antibiotics	 in	 livestock	seem	to	influence	the	occurrence	of	C.	difficile,	but	to	what	
extent	the	usage	affects	the	occurrence	of	C.	difficile	in	livestock	and	in	meat	from	these	animals	
is	not	well	studied.	
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Recommendations	
In	order	to	understand	the	epidemiology	of	community‐acquired	CDI,	to	understand	the	spread	
of	C.	difficile	both	within	the	animal	and	human	reservoir	and	to	compare	cross	countries,	there	
is	 a	 need	 for	 standardized	definitions	 and	 surveillance	methods	 to	 assess	disease	 trends.	 In	
order	to	implement	intervention	to	reduce	and	control	CDI,	national	surveillance	programs	are	
vital	to	monitor	the	incidence	both	in	the	healthcare	system	and	in	the	community,	to	identify	
populations	at	risk	and	characterize	the	molecular	epidemiology	of	strains	causing	CDI.	Experi‐
ence	from	England	and	Wales	shows	that	it	is	possible	to	reduce	the	number	of	severe	CDI	cas‐
es	by	implementing	intervention	in	hospitals	and	nursing	homes.		Surveillance	programs	of	C.	
difficile	should	focus	on	all	types	able	to	produce	toxin	regardless	of	ribotypes.	
	
Comparative	microbiological	 studies,	 using	 discriminatory	methods	 as	MLVA	 and	WGS	 of	C.	
difficile	 strains	 found	 in	humans,	animals,	 food	and	environment	(including	water)	combined	
with	epidemiological	methods,	could	potentially	contribute	to	a	better	understanding	of	C.	dif‐
ficile	and	its	zoonotic	potential.	Focus	should	not	only	be	on	the	highly	virulent	types	but	on	all	
types	 able	 to	 produce	 toxin.	 It	 is	 expected	 that	more	 studies	 in	 the	 future	will	 be	 published	
from	other	countries.	
	
As	C.	difficile	may	 arise	 as	 a	 result	 of	 treatment	with	 cephalosporins	 in	 production	 animals,	
testing	for	the	occurrence	of	C.	difficile	when	testing	for	ESBL20	bacteria	should	be	considered,	
and	especially	in	cattle	where	cephalosporins	are	still	used,	though	phased	out	from	2014.	An‐
other	focus	area	could	be	the	use	of	antibiotics	in	other	animals	as	pets	and	horses,	which	could	
have	an	impact	on	the	occurrence	and	spread	of	C.	difficile	in	the	community.	
	
In	food	production,	four	areas	should	have	special	attention:	A)	Changes	that	favour	anaerobic	
conditions	 in	 the	 food	production,	B)	 antimicrobial	 treatment	 in	animals,	 C)	 changes	 in	 food	
production	and	hygiene	procedures	and	D)	changes	of	heat	treatment	in	the	food	production	
chain.	In	these	four	areas,	awareness	on	possible	effects	on	the	occurrence	C.	difficile	and	the	
survival	of	spores	should	be	kept	in	mind.		
	
New	 food	hygiene	measures	 could	 be	 beneficial	 if	 implemented	 together	with	 recommenda‐
tions	of	 cooking	at	higher	 temperatures	 to	 reduce	 the	prevalence	of	C.	difficile	and	spores	 in	
food	from	productions	facilities	producing	food	for	vulnerable	persons	and	patients	in	risk	of	
CDI	in	e.g.	nursing	homes	and	hospitals.	
	
Even	though	the	role	of	C.	difficile	as	a	zoonotic	agent	 is	not	 fully	understood	and	the	role	of	
food	products	and	a	possible	foodborne	transmission	in	association	with	CDI	is	unknown	the	
detection	of	genes	encoding	for	the	virulent	toxins	TcdA,	TcdB	and	the	binary	toxin	in	food	in‐
tended	for	human	consumption	should	be	considered	as	problematic	and	a	risk	for	C.	difficile	
transmission	to	humans.		
	
	 	
																																																								
	
	
20	ESBL:	Extended‐spectrum	beta‐lactamase	producing	bacteria	
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